

CURRICULUM VITAE

CONTACT INFORMATION:

Name: Peter F. Buckley, M.D.

Business Address: Dean, School of Medicine
Virginia Commonwealth University (VCU)
Executive Vice President for Medical Affairs, VCU Health System

ACADEMIC BACKGROUND:

1980 - 1986 MB Bch BAO (equivalent of an M.D. degree)
University College Dublin
School of Medicine
St. Vincent's University Hospital Dublin,
Ireland
(Undergraduate honors in anatomy, biochemistry, pharmacology, pathology, otolaryngology and surgery).

POSTDOCTORAL TRAINING:

1986 - 1987 Internship
Medical intern - Neurology and Oncology
Surgical intern - Neurosurgery and Hepatobiliary surgery St.
Vincent's University Hospital
Elm Park
Dublin, Ireland

1987 - 1992 Resident in Psychiatry
St. John of God Psychiatric Services
Stillorgan
Dublin, Ireland

1990 - 1991 Research Fellow
St. John of God Psychiatric Services
Stillorgan
Dublin, Ireland

MD THESIS:

1997 Cerebral morphology and metabolism in schizophrenia: relationship to clinical indices.
University College Dublin, Ireland

LICENSURE:

Commonwealth of Virginia Board # 0101266302
Georgia Medical Board # 050870
Ohio Medical Board # 35-06-2952

CERTIFICATIONS AND HIGHER TRAINING:

2011 Dean's Executive Development Program
Association of American Medical Colleges

2007-2008 Council of Deans Fellowship
Association of American Medical Colleges

2007 Executive Leadership Program
Association of American Medical Colleges

2002 Program for Chiefs of Clinical Services
Harvard School of Public Health

1997 Mental Health Leadership Program Weatherhead
School of Business Management Case Western
Reserve University

1996 American Boards of Psychiatry and Neurology (recertification 2006)

1991 FLEX Medical Licensure Examination

1990 Royal College of Psychiatrists Examination

1989 Canadian Overseas Entrance Examination

1989 American Overseas Entrance Examination

CURRENT APPOINTMENTS:

2017 – current Dean, School of Medicine
Virginia Commonwealth University

2017 – current Executive Vice President for Medical Affairs
Virginia Commonwealth University Health System

PROFESSIONAL EXPERIENCE AND ACADEMIC APPOINTMENTS:

Jan. 2020 – Oct. 2020 Interim CEO, VCU Health System

Jan. 2020 – Oct. 2020	Interim Senior Vice President for Health Sciences Virginia Commonwealth University
2016-2017	Executive Vice President for Medical Affairs and Integration Augusta University
2014 - 2016	Interim Executive Vice President for Health Affairs Augusta University
2014 - 2016	Interim Chief Executive Officer AU Medical Associates
2014 - 2016	Interim Chief Executive Officer AU Medical Center
2010 – 2017	Chair, Board of Trustees AU Medical Associates
2011-2017	Dean Medical College of Georgia
2010 - 2011	Interim Dean Medical College of Georgia
2010 - 2010	Senior Associate Dean for Leadership Development Medical College of Georgia
2000 - 2017	Professor of Psychiatry, Professor of Pharmacology, Professor of Radiology Augusta University
2000 - 2010	Professor and Chairman Department of Psychiatry and Behavioral Health Medical College of Georgia
2000 - 2010	Clinical Services Chief of Behavioral Health MCG Health, Inc.
2007 - 2010	Associate Dean for Leadership Development Medical College of Georgia Augusta, Georgia
2001 - 2006	Attending Psychiatrist Veterans Administration Medical Center Augusta, Georgia
1995 - 2000	Medical Director and Vice President for Clinical Affairs Northcoast Behavioral Healthcare System Northfield, Ohio

2000 - 2000	Professor of Psychiatry Case Western Reserve University School of Medicine Cleveland, Ohio
1999 - 2000	Vice Chairman for State Services Department of Psychiatry Case Western Reserve University
1996 - 2000	Associate Professor of Psychiatry Case Western Reserve University
1992 - 1996	Assistant Professor of Psychiatry Case Western Reserve University
1994 - 1995	Medical Director Western Reserve Psychiatric Hospital Northfield, Ohio
1993 - 1994	Consultant Psychiatrist Western Reserve Psychiatric Hospital Northfield, Ohio
1992 - 2000	Attending Psychiatrist University Hospitals of Cleveland Cleveland, Ohio
1992 - 1994	Clinical Director Psychobiology Evaluation and Treatment Program University Hospitals of Cleveland Cleveland, Ohio

COMMITTEE SERVICE ON STATE, NATIONAL AND PROFESSIONAL ORGANIZATIONS:

2021-	Member, FAIMER International Graduates Support Committee, ECFMG
2021-	Secretary elect, Board of Trustees, Richmond Academy of Medicine
2020-	Member, Committee on Contributions, American College of Psychiatrists
2020-	Member, Nominations and Leadership Development Committee, American College of Psychiatrists
2020-	Leadership Awards Committee, Association of American Medical Colleges
2020-	Member, Board of Trustees, Richmond Academy of Medicine
2019-	Chair, Council of Deans Administrative Board, Association of American Medical Colleges
2019-	Member, USMLE Committee on Individualized Review, National Board of Medical Examiners
2019-	Co-Chair, University of California Riverside School of Medicine National Advisory Board

2018-2020 Member, Guideline Writing Group for *Practice Guideline for the Treatment of Patients with Schizophrenia*, American Psychiatric Association

2018-2021 Member, Board of Directors, Richmond Behavioral Health Authority Foundation

2018- Member, Board of Directors, Association of American Medical Colleges

2018-2019 Chair elect, Council of Deans Administrative Board, Association of American Medical Colleges

2018- Member, Executive Committee, and Schizophrenia International Research Society

2018- Member, Governance Committee, Development Committee, Educational Commission of Foreign Medical Graduates (ECFMG)

2018- Chair, Medical Education Credentials Committee, Educational Commission of Foreign Medical Graduates (ECFMG)

2017- Member, Board of Trustees, Educational Commission for Foreign Medical Graduates (ECFMG)

2017- Member, Advocacy Committee, Medical Society of Virginia (MSV)

2017- Member, MSV Academic Deans' Forum

2016-2019 Chair, Board of Directors, WCG Research Foundation (for compassionate need and research ethics)

2016 Member, Committee on Research Awards, American Psychiatric Association

2014- Member, Council of Deans Administrative Board, Association of American Medical Colleges

2014-2019 Chair, Council of Deans Fellowship Committee, Association of American Medical Colleges

2014-2016 Member, Board of Directors, University Health System Consortium

2014-2016 Co-Chair, Georgia Mental Health and Physical Health Integrations Task Force, Carter Presidential Center

2014-2018 Member, Psychiatry Maintenance of Certification Committee, American Board of Psychiatry and Neurology

2013-2017 Member, Executive Committee, International Congress on Schizophrenia Research

2013-2016 Member, Election Committee, Schizophrenia International Research Society

2012 Member, Council of Deans Workgroup on Graduate Medical Education, Association of American Medical Colleges

2012 Council of Deans Liaison, Group on Resident Affairs, Association of American Medical Colleges

2012-2013 Member, Accreditation Review Team, Liaison Committee for Medical Education (LCME)

2011-2013 Workgroup on the Role of Psychiatry in Healthcare Reform, American Psychiatric Association

2011-2014 Board of Directors, University Hospital System Hospice

2011-2014 Member - Consultant, Membership Committee, American Psychiatric Association

2010-2011 Member, Council of Deans Fellowship Committee, Association of American Medical Colleges

2010 Member, Innovations Working Group, Council of Academic Societies, Association of American Medical Colleges

2010-2015 Member, External Advisory Board, South Carolina Clinical and Translational Research Institute (CTSA), Medical University of South Carolina

2009-2013 Chair, PanAmerican International Division Royal College of Psychiatrists

2009-2015 Chair, Dean's Committee, American College of Psychiatrists

2009 - 2010 Member, PhenX Psychiatric Genetics Workgroup, National Human Genome Research Institute

2009-2011 Member, Distinguished Fellow Committee, Georgia Psychiatric Physicians Association

2009-2010 Member, Task Force on Mental Health Workforce, Georgia Board of Regents

2008-2010 Member, Leadership Selection and Development Task Force, Association of American Medical Colleges

2008-2015 Member, Deans Committee, American College of Psychiatrists

2008-2010 Member, Board of Directors, American Psychiatric Institute for Research and Education

2008-2010 Chair, Travel Fellowship Award Committee, Society of Biological Psychiatry

2008 Member, Hospital Subcommittee, Georgia Gubernatorial Task Force on Mental Health

2007-2010 Member, Committee on Graduate Medical Education and Lifelong Learning, American Psychiatric Association

2007-2008 Research Mentorship Colloquium, American Psychiatric Institute for Research and Education

2007 Member, Travel – Fellowship Award Committee, Society of Biological Psychiatry

2006-2008 President, American Association of Chairs of Academic Departments of Psychiatry

2006 Steering committee, Schizophrenia Initiative, International Society for CNS Drug Development

2006- Member, Scientific Council, National Alliance for Research in Schizophrenia and Affective Disorders – Brain and Behavior Research Foundation

2006-2017 Chairman, CME committee for Georgia Psychiatric Physicians Association

2005-2009 Member, Executive Committee, Royal College of Psychiatrists, PanAmerican Division

2005 Member, Gubernatorial Task Force on Mental Health Commission for a New Georgia

2004-2006 President-Elect, American Association of Chairs of Departments of Psychiatry

2004 Georgia's Policy Academy for Substance Abuse Co-Occurring Disorders

2004-2009 Board of Directors, National Foundation for Mental Health

2004-2015 Member, Advisory Board, International Congress on Schizophrenia Research

- 2004-2014 Member, Board of Directors, Central Savannah River Area Partnership for Community Health
- 2003 Agitation Expert Panel, International Psychogeriatric Association
- 2003 Rosalynn Carter Mental Health Forum
- 2003- Richmond County Medical Society
 - President
 - Secretary, Board of Directors
 - Treasurer, Board of Directors
 - Chair, Alliance Committee
 - Mental Health Committee
- 2002-2015 Member, Scientific Council, National Alliance on Mental Illness
- 2002-2009 Executive Committee, American Association of Chairs of Departments of Psychiatry
- 2002-2006 Board of Trustees, Georgia Psychiatric Physicians Association
- 2001-2010 Medical Advisor, National Alliance on Mental Illness, Augusta, Georgia
- 1996-2000 Medical Advisor, Alliance for the Mentally Ill - Metro-Cleveland and Cuyahoga County
- 1994-2000 Cuyahoga County Mental Health Board
 - Medical Directors Committee
 - Morbidity and Mortality Committee
 - Advisory Committee, Research Institute

SERVICE ON FEDERAL GRANT REVIEW COMMITTEES:

- 2021 Chair, Data Safety and Management Board, National Institute of Mental Health
- 2021 Member, Loan Repayment Program Review, National Institute of Mental Health
- 2020 Chair, Mental Health Services Research Special Emphasis Panel, National Institute of Mental Health
- 2020 Chair, Clinical High Risk for Psychosis Special Emphasis Panel, National Institute of Mental Health
- 2020 Member, Fogarty National Brain Disorders, Special Emphasis Panel, National Institute of Mental Health
- 2020 Chair, Data Safety and Management Board, National Institute of Mental Health
- 2020 Member, Special Emphasis Panel, Loan Repayment Panel, National Institute of Mental Health
- 2019 Member, Special Emphasis Panel, Addictions, Depression, Bipolar Disorder, Schizophrenia, National Institute of Mental Health
- 2019 Member, Special Emphasis Panel, Fogarty Global Brain Disorders, National Institute of Mental Health
- 2018 Chair, Special Emphasis Panel, Neural Basis of Psychopathology, Addictions, and Sleep Disorders Study Section, National Institute of Mental Health
- 2018 Member, Special Emphasis Panel, Neural Basis of Psychopathology, Addictions, and Sleep Disorders Study Section, National Institute of Mental Health

2017 Member, Fogarty Global Program, Review, National Institute of Health

2017 Chair, Interventions/Biomarkers Special Emphasis Panel, National Institute of Mental Health

2016 Chair, Special Emphasis Panel, Neural Basis of Psychopathology, Addictions, and Sleep Disorders Study Section, National Institute of Mental Health

2016 Member, Veterans Affairs Research Review Panel

2016 Chair, Special Emphasis Panel, Confirmatory Efficacy RFA, National Institute of Mental Health

2016 Chair, Special Emphasis Panel, Early Psychosis Intervention, National Institute of Mental Health

2014 Chair, Special Emphasis Panel, Early Psychosis Intervention, National Institute of Mental Health

2013 Co-Chair, Special Emphasis Panel, Clinical and Translational Science Award (CTSA) Review, National Institute of Allergy and Infectious Diseases

2011 Chair, National Institute of Mental Health, Special Emphasis Panel, Summer Research Experience Program, R25 Review

2011 Chair, Joint National Institute of Neuromuscular Diseases and National Institute of Mental Health Special Emphasis Panel, R25 Review

2011 Chair, National Institute of Mental Health, Summer Research in AIDS and Mental Health Special Emphasis Panel, R25 Review

2010 Member, Special Emphasis Panel, P30 Grant Review, National Institute of Mental Health

2010 Chair, Special Emphasis Panel, R 25 Grants Review, National Institute of Mental Health

2010 Member, Special Emphasis Panel, P50 Grant Review, National Institute of Mental Health

2009 ARRA Federal Grant Reviewer

- Reviewer for Challenge Grants
- Chair, Administrative Supplements Review Panel, NIMH
- Chair, P30 Review Panel, National Institute of Mental Health
- Chair, ARRA Review Panel, NIMH

2009 Member, Special Emphasis Panel, P50 grant Review, NIMH

2007 Mental Health Centers for Intervention Development and Applied Research (CIDAR), Special Member and Review Panel, National Institute of Mental Health

2006 Member Special Emphasis Panel, T32 Diversity Grants, National Institute of Mental Health

2002-2004 Member, Interventions Research Review Committee, National Institute for Mental Health

2006-2009 Chair, Interventions Committee for Disorders Related to Schizophrenia, Late life or Personality (ITSP), National Institute of Mental Health

2006- Member, Data and Safety Monitoring Board Committee, National Institute of Mental Health

2006 Member, Schizophrenia and Aging Special Emphasis Panel, National Institute of Mental Health

- 2006-2010 Member, National Institute of Mental Health Loan Repayment Program Special Review Panel
- 2004-2005 Chair, Special Emphasis Panel, National Institute of Mental Health

INSTITUTIONAL COMMITTEE SERVICE:

- 2017- Virginia Commonwealth University - VCU Health System
- Medical Executive Committee
 - VCUHS CEO's Cabinet meeting
 - VCUHS Leadership Council
 - VCUHS Quality Council
 - MCVP Board of Directors
 - UHS Professional Education Programs, Board of Directors
 - UHS, Board of Trustees
 - Council of Deans
 - Health Sciences Deans
 - Co-Chair, National Prominence Work Group, VCU Strategic Plan
 - Executive Sponsor, VCU Health System Strategic Plan
 - Member, VP Research Search Committee
 - Member, VCU Medical Center CEO Search Committee
 - MCV Foundation, Next Advisory Board
 - University Council
 - Board of Directors, VCU Health System
 - Virginia Premier Health Plan Board
 - Children's Hospital of Richmond at VCU, Brook Road, Board
 - President's Executive Cabinet
 - President's "Group of 5"
 - Executive Committee, VCU Incident Command Team
 - VCU Hiring Freeze Committee
 - Cancer Center, Internal Advisory Board
 - Co-Chair, VP University Relations Search Committee
- 2012-2017 University System of Georgia
- Academic Health Planning Workgroup
 - Georgia Board of Regents' Educational Assessment Team (GREAT)
- 2000-2017 Augusta University (Formerly Georgia Regents University - GRU)
- Transformation 2020 Strategic Planning Leadership Team
 - AU President's Executive Cabinet
 - AU President's Cabinet
 - MCGHS Senior Leadership
 - MCGHS Board of Trustees
 - MCGHI Board of Trustees
 - Chair, MCGHS Quality Committee
 - MCGHI Board of Trustees Planning and Development Committee
 - Ad Hoc Columbia County Finances Committee, Physicians Practice Group
 - Bylaws Committee, Physicians Practice Group
 - Clinical Growth Advisory Committee, Physicians Practice Group

- Clinical Executive Committee
- Medical Executive Committee
- Managed Care Committee, Physicians Practice Group
- Executive Committee, Physicians Practice Group
- Board of Trustees, Physicians Practice Group
- Ambulatory Access Workgroup
- Department Advisory Group, Psychiatry & Health Behavior
- Dean's Council
- Co-Chair, Enterprise-Wide Rapid Strategic Planning
- Chair, Board of Trustees, Physician Practice Group
- GHS Clinical Enterprise Workgroup
- Internal Advisory Board, Brain Discovery Institute
- Co-Chair, School of Medicine Strategic Planning Team
- School of Medicine Dean's Task Force on Faculty Retention
- School of Medicine Dean's Staff Committee
- School of Medicine Dean's Staff Review Team
- School of Medicine Academic Affairs Deans Committee
- School of Medicine Dean's Task Force on Diversity
- School of Medicine Dean's Task Force on Faculty Forward Program
- School of Medicine Dean's Clinical Executive Committee
- School of Medicine Chair, Search Committee for Chair of Medicine
- School of Medicine Co-Chair, Search Committee for Chair of Pathology
- School of Medicine Chair, Search Committee for Chair of Pediatrics
- School of Medicine Search Committee for Regional Dean, Athens Campus
- School of Medicine Search Committee for Associate Dean for Diversity
- School of Medicine Chair, Departmental Review, Anesthesiology
- School of Medicine Intramural Grants Program Review Committee
- School of Medicine Neuroscience Brann Awards Review Committee
- Planning Committee, Clinical and Translational Science Award Program (CTSA)

2000-2017 Veterans Affairs Medical Center, Augusta, Georgia

- Dean's Committee
- Research Committee

1995-2000 Northcoast Behavioral Healthcare System

- Governing Body
- Governing Council
- Chairman, Medical Executive Committee
- Chairman, Medical Staff Committee
- Chairman, Clinical Affairs Committee
- Chairman, Mortality and Morbidity Committee
- Chairman, Research Committee

1994-2000 Ohio Department of Mental Health

- Drug Utilization and Evaluation Committee
- Continuing Medical Education Committee
- Steering Committee, ODMH and Hospital Reengineering
- President, Medical Directors Association
- Co-chair, Clinical Coordinating Committee

- Co-leader, Community Support Network Clinical Product Line
- Mediation representative, ODMH v's Ohio Mental Health Boards
- Northeast Collaborative
- Northwest Collaborative
- Steering Committee, Mental Health Recovery and Best Practices

- 1993-2000 University Hospitals of Cleveland, Department of Psychiatry
- Executive Committee
 - Continuing Medical Education Advisory Committee
 - Research Committee
 - Student Clerkship Steering Committee
 - Credentialing Committee
 - Co-Chairman, Carepath Development Committee
 - Quality Assurance Committee

CONSULTANT TO STATE AND NATIONAL PROFESSIONAL ORGANIZATIONS:

American Pharmacists Association
 CawleyJohnson Group (Behavioral Management Solutions)
 Comprehensive Neuroscience, Inc.
 Georgia Medical Licensure Board
 Neuroleptic Malignant Syndrome Information Services
 New York Department of Mental Health
 Texas Department of Mental Health
 University of Maryland School of Medicine

MEMBERSHIPS:

Alpha Omega Alpha Honors Society
 American Association of Chairs of Departments of Psychiatry (complete 2010)
 American Association of Community Psychiatrists (complete 2009)
 American College of Physician Executives (complete 2016)
 American College of Psychiatrists
 American Medical Association
 American Psychiatric Association
 Collegium Internationale Neuro-Psychopharmacologicum (complete 2012)
 Council of Deans, Association of American Medical Colleges
 Georgia Psychiatric Physicians Association (complete 2017)
 International Early Psychosis Association (complete 2010)
 Medical Association of Georgia (complete 2017)
 Medical Society of Virginia
 Mental Health Association of Greater Augusta (complete 2017)
 National Alliance on Mental Illness
 National Alliance on Mental Illness - Augusta, Georgia (complete 2016)
 Richmond Academy of Medicine
 Richmond County Medical Society (complete 2017)
 Rotary International, Augusta Club (complete 2017)
 Royal College of Psychiatrists

Schizophrenia International Research Society
Society of Biological Psychiatry (complete 2015)
Southern Psychiatric Association (complete 2009)

PROFESSIONAL DISTINCTIONS:

2021 Strauss Award for Extraordinary Service, Medical College of Virginia Foundation

2021 Top Psychiatrist, Virginia Top Doctors

2020 Virginia 500, Virginia Business Listing of Most Influential Leaders

2019 Douglas D. Bond Visiting Professor and Endowed Lectureship, Case Western Reserve University, Department of Psychiatry

2017 Distinguished Service Award, Georgia Psychiatric Physicians Association

2016 Strecker Award and Endowed Lectureship, University of Pennsylvania, Department of Psychiatry

2015 Top 50, Irish American Healthcare and Life Sciences

2015 Medical Trailblazer Award, Augusta City Classic

2015 Inaugural 'Spirit of MCG' Award for Excellence in Leadership, MCG Faculty Senate

2014 Kempf Fund Award for Psychobiological Research and Mentorship in Schizophrenia, American Psychiatric Association

2014 Esner Visiting Professor and Endowed Lectureship, Department of Psychiatry, Michigan State University

2013 Lamartine Hardman Cup Award for Exemplary Physician Leadership, Medical Association of Georgia

2013 Donald Goff Visiting Professor and Endowed Lectureship, Department of Psychiatry, Harvard Medical School

2013 Presidential Commendation for Leadership Accomplishments, American Psychiatric Association

2013 Fellow, American College of Psychiatrists

2012 Cancro Academic Leadership Award, American Academy of Child and Adolescent Psychiatry

2011-2012 Who's Who in Medicine and Healthcare

2011 Meyer Haber Visiting Professor, Department of Psychiatry, Case Western Reserve University

2011 Wayne Fenton Award for Excellence in Clinical Care, Schizophrenia Bulletin

2010 Hero Award, National Alliance on Mental Illness, Augusta Chapter

2007-2008 Fellow, Council of Deans, Association of American Medical Colleges

2007 Distinguished Fellow, American Psychiatric Association

2006 Psychiatrist of the Year, Georgia Psychiatric Physicians Association

2006 Fellow, Royal College of Psychiatrists

2006 Henry and Amelia Nasrallah Visiting Professor, Department of Psychiatry, Ohio State University

2004 Administrative Psychiatry Award, American Psychiatric Association

2002- Best Doctors in America

2001 Marquis' Who's Who in America

1999 Lilly Schizophrenia Reintegration Award

1998 Exemplary Psychiatrist Award, National Alliance on Mental Illness

1995 Mead Johnson Award, American College of Neuropsychopharmacology

1993 Young Investigator Award, International Congress on Schizophrenia Research

1992 Young Investigator Award, Winter Workshop on Schizophrenia Research

1991 Royal Academy of Medicine Ireland, Senior Resident Research Award

OTHER LEADERSHIP/TEAM DISTINCTIONS:

2020 Becker's Healthcare, Top 100 US Hospitals (interim CEO/SVP)

2020 The Lown Institute, Top 50 Academic Hospitals (Interim CEO/SVP)

2019 American Heart Association, Heart Walk, Richmond (Co-Chair)

2017 AE Baldwin Award, Accreditation Council for Graduate Medical Education, for Professionalism and Excellence in Residents Training, VCU (Dean)

2014 Philanthropy 50, Chronicle of Philanthropy - \$66 Million Endowment to Medical College of Georgia (Dean)

2012 Award for Creativity in Psychiatric Education, American College of Psychiatrists (Project Director)

2009 Best Publication Award, American Media (Editor, Clinical Schizophrenia and Related Psychosis)

2003 Visiting Professor Award, Pfizer (Departmental Chair)

2001 Visiting Professor Award, Janssen (Departmental Chair)

1999 Best Psychiatric Hospital in Ohio Award, National Alliance on Mental Illness (Medical Director)

1998 JCAHO Commendation with Eleven Best Practices (Medical Director)

REFEREE:

Journals:

Academic Psychiatry

Acta Neuropsychiatrica

Acta Psychiatrica Scandinavica

Administration and Policy in Mental Health and Mental Health Services Research

Advances in Schizophrenia and Clinical Psychiatry
Advances in Therapy
Aggressive Behavior
American Journal of Managed Care
American Journal of Psychiatry
Annals of General Psychiatry – JAMA Psychiatry
Annals of Psychiatry and Mental Health
Archives of General Psychiatry
Behavioral Brain Research
Behavioral Sciences and the Law
Bipolar Disorders
Biological Psychiatry
BMC Psychiatry
BMC Medical Research Methodology
BMJ Open
Brain Behavioral Research
British Journal of Psychiatry
British Medical Journal
Clinical Investigation
Clinical Neuropharmacology
CNS Drugs
CNS Spectrums
Cognitive, Affective, and Behavioral Neuroscience
Community Mental Health Journal Comprehensive
Psychiatry
Current Molecular Pharmacology
Current Pharmacogenomics
Depression and Anxiety
Drugs
Early Intervention Psychiatry
European Journal of Clinical Investigation
European Psychiatry
Expert Opinion on Drug Metabolism and Toxicology
Expert Opinion on Drug Delivery
Expert Opinion on Investigational Drugs
Expert Opinion on Pharmacotherapy
Expert Review of Neurotherapeutics
Expert Review of Pharmacoeconomics & Outcomes Research
Focus
Future Neurology
Harvard Review of Psychiatry
Human Psychopharmacology
International Clinical Psychopharmacology International
Journal of Developmental Neuroscience International

Journal of Mental Health & Psychiatry International
Journal of Neuropsychopharmacology International
Journal of Psychiatry in Medicine
Irish Journal of Psychological Medicine
Journal of Abnormal Psychology
Journal of Addiction
Journal of Affective Disorders
Journal of Behavioral Health Services and Research
Journal of Clinical Outcomes Management
Journal of Clinical Pharmacology
Journal of Clinical Psychopharmacology
Journal of Critical Illness
Journal of Mental Health
Journal of Nervous and Mental Disease
Journal of Neurology, Neurosurgery and Psychiatry
Journal of Psychiatric Practice
Journal of Psychiatric Research
Journal of Psychiatry: Open Access
Journal of Psychiatry and Neuroscience
Journal of Psychosomatic Research
Journal of Sex and Mental Therapy
Journal of the American Academy of Child and Adolescent Psychopharmacology
Lancet
Lancet Psychiatry
Life Sciences
Mind
Molecular Psychiatry
Neurochemical Research
Neurodegenerative Diseases
NeuroMolecular Medicine
Neuropsychobiology
Neuropsychiatric Disease and Treatment
Neuropsychiatric Genetics
Neuroscience and Biobehavioral Reviews
Neuroscience Letters
npj Schizophrenia
Pharmacoeconomics
Pharmacopsychiatry
Pharmacy and Therapeutics
PLoS ONE
Primary Psychiatry
Primary Care and Community Psychiatry
Progress in Neuro-Psychopharmacology & Biological Psychiatry
Progress in Neurobiology

Psychiatric Services
Psychiatry 2006
Psychiatry: Interpersonal and Biological Processes
Psychiatry Research: Neuroimaging
Psychiatric Times
Psychoneuroendocrinology
Psychotherapy and Psychosomatics
Primary Psychiatry
Research and Therapy
Reviews on Recent Clinical Trials
Schizophrenia Bulletin
Schizophrenia Research
Schizophrenia Research and Treatment
Schizophrenia Research: Cognition Social
Science & Medicine
The Medical Letter
Therapeutics and Clinical Risk Management
Thomas Rewter's Drug Profiles
Trends in Molecular Medicine

Books:

American Psychiatric Press
American Journal of Psychiatry
Cambridge University Press
Harper Collins Publications
Harworth Press
Journal of Clinical Psychiatry
Journal of Dual Diagnosis
Journal of Nervous and Mental Diseases
Lippincott Williams and Wilkins
Norton Publications
Oxford University Press
Psychiatric Clinics of North America
Psychiatric Services
Psychiatric Times

Grants and Awards:

Academy of Medical Sciences, England (2019)
American Psychiatric Association, Gold Achievement Award (2004)
Association of American Medical Colleges Awards (2020)
Canadian Foundation for Innovation (2007)
Canadian Institutes of Health Research (2002; 2007; 2011)
Dutch National Research Foundation (2008)
Executive Leadership in Academic Medicine (2013 - 2019)
Finland National Research Institute (2007)

Foundation for Advancement of International Medical Education and Research [FAIMER] (2019)
 Health Research Board, Ireland (2005; 2007; 2012)
 National Alliance for Research in Schizophrenia and Affective Disorders/Brain and Behavior
 Research Foundation

- Distinguished Investigator Award (2009; 2013; 2016)
- Independent Investigator Award (2007-2009; 2013; 2016)
- Young Investigator Award (2006 -)

 National Institute for Drug and Alcohol (2007)
 National Institute of Mental Health (2002 -)
 National Institute for Health Research Trust-National Health Services, England (2006; 2011; 2013)
 New York University Arab Emirates Collaborative Project (2011)
 New Zealand Research Council (2019)
 Medical Research Council, England (2009-)
 RAND Foundation, England (2012)
 Reine Foundation, Australia (2006)
 Spanish-Catalan Research Foundation (2009)
 Stanley Medical Research Institute (2015)
 Thrasher Foundation, (2006; 2009)
 Veterans' Administration Merit Research Program (1995; 2001)
 Wellcome Foundation Trust, England (1996)
 Young Investigator Award, International Congress on Schizophrenia Research (1995; 1997; 1999; 2001; 2003)
 Young Investigator Award, Society for Biological Psychiatry (2007-2010)
 Young Investigator Colloquium Award, American Psychiatric Association (2002; 2007; 2008)

Consensus Guidelines/Activities:

2020 American Psychiatric Association, Treatment Guidelines for Schizophrenia, contributor
 2019 American Psychiatric Association, DSM-5-TR, expert reviewer
 2015 National Academy of Medicine, Patient and Family Center Care report, expert reviewer
 2014 National Academy of Medicine, Veteran's Affairs report, expert reviewer
 2009 Schizophrenia PORT recommendations, contributor
 2006 Roadmap for the Treatment of Schizophrenia, contributor
 2006 Texas Medication/Algorithm for Treatment of Schizophrenia, contributor
 2004 Expert Consensus Guidelines, Contributor, Treatment of Behavioral Emergencies
 2004 Schizophrenia PORT recommendations, contributor
 2004 American Psychiatric Association treatment guidelines for schizophrenia, reviewer
 2004 Texas Medication Algorithm for the treatment of schizophrenia, contributor
 2003 Expert consensus guidelines on optimizing pharmacologic treatment for psychotic disorders, contributor

EDITORIAL ACTIVITIES:

- Editorial Board, Biomarkers in Neuropsychiatry (2019-)
- Editor-in-Chief, Schizophrenia and Related Psychoses (2008-2019)
- Editor-in-Chief, Journal of Dual Diagnosis (2004-2010)
- Annual Co-Editor, Mosby Yearbook of Psychiatry (2005-2013)
- Associate Editor, Journal of Nervous and Mental Disease (2010-)
- Advisory Board, Focus (2011-)
- Advisory Board, Psychiatric Clinics of North America (2011-2015)
- Editorial Board, Irish Journal of Psychological Medicine (2013-)
- Editorial Board, Psychiatric Rehabilitation Journal (2012-)
- Editorial Board, Schizophrenia Research (2010-)
- Editorial Board, Schizophrenia Bulletin (2010-)
- Editorial Board, Journal of Healthcare Leadership (2009-2010)
- Editorial Board, Current Psychiatry (2007; Consulting Editor, 2011-)
- Editorial Board, Psychiatric Times (2005-)
- Editorial Board, Innovations in Clinical Neuroscience [formerly Psychiatry] (2007-2009)
- Editorial Board, Neuropsychiatry Reviews (2008-2010)
- Editorial Board - Reviews on Recent Clinical Trials (2007-2011)
- Editorial Board, Psychiatric Issues in Emergency Care Settings (2004-2008)
- Editorial Board, Mental Health Outcomes (2003-2004)
- Editorial Board, American Journal of Managed Care (1998-2003)
- Editorial Board, Treatment Research Applications (2000-2002)
- Editorial Board, Academic Psychiatry (2004-2006)
- Governance Board, Academic Psychiatry (2006-2010)
- Chair, Schizophrenia Special Report, Psychiatric Times (2019)
- Guest Editor, Focus (2020)
- Guest Co-Editor, Psychiatric Annals (2021)
- Guest Co-Editor, Psychiatric Annals (2020)
- Guest Co-Editor, Psychiatric Annals (2018)
- Guest Co-Editor, Psychiatric Annals (2018)
- Guest Co-Editor, Psychiatric Annals (2013)
- Guest Co-Editor, Schizophrenia Bulletin (2013)
- Guest Co-Editor, Focus, American Psychiatric Press (2008)
- Guest Co-Editor, Focus, American Psychiatric Press (2012)
- Guest Co-Editor, Focus, American Psychiatric Press (2020)
- Guest Editor, CNS Spectrum, Supplement (2004, 2008)
- Guest Editor, Journal of Clinical Psychiatry Supplement (2008)
- Guest Co-Editor, Resident and Staff Physician, Supplement (2007)
- Guest Editor, Journal of Clinical Psychiatry Supplement (2007)
- Guest Editor, Treatment Research Applications (2004)
- Guest Editor, Psychoses Monograph, Psychiatric Times (2003)
- Guest Co-Editor, Psychiatric Issues in Emergency Care Settings, supplement (2003)
- Guest Co-Editor, American Journal of Managed Care, supplement (2002)

FEDERAL, STATE AND FOUNDATION RESEARCH SUPPORT:

- 2021- Co-Investigator: African Ancestry – Genomic Psychiatry Cohort. National Institute of Mental Health, R01. (subcontract pending)
- 2016-2019 Consultant: A Randomized Control Trial of Tocilizumab in Schizophrenia. Brain and Behavior Research Foundation.
- 2016-2019 Consultant: A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia. Stanley Medical Research Institute.
- 2015-2020 Co-Investigator: African American and Genomic Psychiatry Cohort. National Institute of Mental Health, UO1.
- 2015-2019 Co-Investigator: Bipolar-Schizophrenia Network for Intermediate Phenotypes II. National Institute of Mental Health, RO1.
- 2015-2016 Co-Investigator: Adjunct Aripiprazole for Symptomatic Hyperprolactinemia in Female Schizophrenia. National Institute of Mental Health, RO1.
- 2012-2015 Co-Investigator: e-CAeSAR: Evaluation of a Cognitively Adaptive e-treatment in Schizophrenia-diagnosed Adults: A Remediation-based Approach. National Institute of Health/Brain Plasticity, Inc., UO1.
- 2012-2017 Co-Investigator and Mentor: A Potential State and Relapse Predictive Marker in Schizophrenia: Cross-Sectional Study of Serum IL-6 Levels in Schizophrenia. National Institute of Mental Health, K08.
- 2012-2015 Co-Investigator: Medical Students' Suicide Risk Assessment Proficiency after Interaction with a Virtual Patient in Crisis. American Foundation for Suicide Prevention.
- 2012-2013 Co-Investigator: A Randomized, Controlled Study Using Virtual Patients to Enhance Medical Students' Empathic Communication. The Arnold P. Gold Foundation.
- 2010-2013 Co-Investigator: Studying Metabolomics of Antipsychotics' Response to Treatment (SMART). National Institute of Mental Health, RO1.
- 2010-2013 Co-Investigator: ACLAIMS Treatment of relapse in schizophrenia. Columbia University and the Foundation for the National Institute of Health, UO1.
- 2010-2013 Co-Investigator: BDNF/TrkB co-signaling.: a possible therapeutic target for schizophrenia. National Institute of Mental Health, RO1.
- 2009-2012 Consultant: Recovery after an Initial Schizophrenic Episode (RAISE). National Institute of Mental Health, UO1.
- 2009-2011 Co-Investigator: Cognitive Remediation in the Schizophrenia Trials Network (CRiSTN). University of North Carolina at Chapel Hill and the Foundation for the National Institute of Health, UO1.
- 2009-2012 Co-Investigator: Inflammation and Sub-Clinical Renal Damage in Cocaine-Dependent African Americans. National Institute on Drug Abuse, R03.
- 2009-2014 Consultant: Citalopram in First Episode Schizophrenia. National Institute on Mental Health, RO1.

- 2008-2009 Co-Principal Investigator: Patient and Family Centered Care. Challenge Grant. Picker Foundation.
- 2008-2015 Co-Investigator: Genomic Psychiatry Cohort, National Institute of Mental Health, UO1.
- 2008-2010 Co-Investigator: Comparison of Optimal Antipsychotic Treatments for Schizophrenia (COATS). University of North Carolina at Chapel Hill and the Foundation for the National Institutes of Health.
- 2008-2011 Co-Investigator: Pharmacogenetics of Relapse in Schizophrenia, National Institute of Mental Health, UO1 supplement.
- 2008 - 2011 Principal Investigator: Relapse and schizophrenia: Brain Neurotrophins, National Institute of Mental Health, UO1 supplement.
- 2008 - 2010 Co-Investigator: Comparison of Antipsychotics for Metabolic Problems: University of North Carolina at Chapel Hill and the Foundation for the National Institutes of Health.
- 2006 - 2011 Principal Investigator: Relapse prevention in schizophrenia: atypical antipsychotics. National Institute of Mental Health, UO1.
- 2005 - 2006 Co-Principal Investigator: Recovery Oriented Services. Department of Veterans Affairs.
- 2005 - 2008 Principal Investigator: Implementing the recovery model. Georgia Division of Mental Health, Developmental Disabilities, and Addictive Diseases.
- 2001 - 2004 Co-Investigator: The Role of Oxidative Stress in Schizophrenia. National Institute of Mental Health, RO1.
- 2000 - 2003 Principal Investigator: Implementing the recovery model. Ohio Department of Mental Health.
- 1999 - 2001 Principal Investigator: Studies of the standard of care for persons with schizophrenia who incur violent incidents. Stanley Foundation.
- 1996 - 1998 Principal Investigator: Structural and functional brain imaging in schizophrenia, Sihler Foundation.
- 1996 - 2001 Recipient of student scholarship grant, Stanley Foundation.
- 1994 - 1996 Principal Investigator: Magnetic resonance spectroscopy and aberrant neurodevelopment: a comparison between patients with schizophrenia and autism. Stanley Foundation.
- 1993 - 1995 Co-Investigator: A comparison of clozapine treatment and standard neuroleptic treatment in treatment refractory schizophrenia. Sihler Foundation.
- 1992 - 1994 Co-Investigator & Core Director of Psychopathology and Assessment of the Cleveland Mental Health Clinical Research Center, National Institute of Mental Health.
- 1992 - 1994 Associate Director, Schizophrenia module, Cleveland Mental Health Clinical Research Center. National Institute of Mental Health.
- 1992 - 1995 Principal Investigator: Functional magnetic resonance imaging in schizophrenia. National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD).

1991 - 1996 Co-Founder & Co-Investigator of Health Research Board of Ireland Schizophrenia Research Unit.

EDUCATIONAL AND MENTORSHIP ACTIVITIES:

Virginia Commonwealth University:

VCUHS Leadership Academy mentor and lecturer
VCU Grace E. Harris Leadership program mentor and lecturer
Medical Student Simulation Lab Preceptor
Psychiatry Residents Small Group Leader
Fogarty International Humphrey Fellowship Program, advisor

Augusta University - Medical College of Georgia (formerly Georgia Regents University/Georgia Health Sciences University):

Leadership academy co-founder and lecturer
Medical student core curriculum lecturer
Medical student clerkship faculty supervisor
Medical student MD/PhD faculty mentor
Deans Ad Hoc daily review team for 2008 LCME accreditation
Resident didactics lecturer
Neuroscience Postgraduate curriculum lecturer
Mini-medical school lecturer
Mentor for overseas medical students, residents, faculty and observerships
Graduate Student Thesis Advisor
Postgraduate Nursing Thesis Advisor
Psychopharmacology Preceptorship Director
Resident faculty supervisor
Psychotic Disorders Fellowship advisor
Master of Public Health (MPH) Mentor and Advisor

Case Western Reserve University:

Residents-supervisor for MetroHealth CWRU residents on rotation
Forensic fellowship - contract supervisor for CWRU fellows on rotation
Continuing Medical Education Director for CWRU CME activities at Northcoast
Undergraduate Thesis advisor

National/International:

American Board of Psychiatry and Neurology (ABPN) Examiner
Stanley Award Student Mentor
Co-author of Psychiatry Board Review Study Guide
Author of postgraduate book on psychiatry
British Medical Journal-Point of Care Monograph
Faculty of 1,000
Up-to-Date

National Board of Medical Examinations-question content expert
Invited departmental grand rounds speaker (over 30 nationally) CME
national symposia Faculty and Course Director
Duke CME, Faculty External Program Reviewer
Medscape, External Reviewer
Georgia Psychiatric Physician Association: CME Committee Chair and Program Director American
Psychiatric Association International Medical Graduate Colloquium-Faculty Mentor American
Psychiatric Association Junior Investigator Colloquium-Faculty Mentor
American Association of Chairs of Departments of Psychiatry- Fellowship Mentor
Executive Leadership in Academic Medicine, Awardee Mentor
External Thesis Examiner, Royal College of Surgeons of Ireland
Thesis Advisor, University of Stellenbosch, South Africa
Association of American Medical Colleges, Council of Deans – Chair, Mentor, Fellow
Lead Virginia, Leadership Mentorship Program, Lecturer

REPRESENTATIVE NATIONAL AND INTERNATIONAL CONFERENCE PRESENTATIONS:

(Hundreds of professional and public presentations since 1987 not listed)

Annual meeting of the Association of American Medical Colleges
Annual meeting of the American Society for Clinical Psychopharmacology
Annual meeting of the American Psychiatric Association (including Presidential Symposia)
Annual meeting of the National Conference on Drug Update and Evaluation (NCDUE) Annual
meeting of the American College of Neuropsychopharmacology
Annual meeting of the Royal College of Psychiatrists
Annual meeting of the British Association of Psychopharmacology
Annual meeting of the Society of Biological Psychiatry
Annual meeting of the American Society for Addiction Medicine
Annual meeting of the Alabama Psychiatric Society
Annual meeting of the Ohio Psychiatric Society
Annual meeting of the Georgia Psychiatric Physicians Association
Annual meeting of the Southern Psychiatric Association
Annual meeting of the Egyptian Psychiatric Association
Annual meeting of the College of Psychiatric and Neurologic Pharmacists
Annual meeting of the Italian Psychiatric Association
Annual conference of the American Correctional Health Services Association
Carter Presidential Center, 30th Annual Mental Symposium
Collegium Internationale Neuro-Psychopharmacologicum
Council of Deans, Association of American Medical Colleges
Council of Academic Societies, Association of American Medical Colleges
European Collegium on Neuropsychopharmacology
Institute of Medicine
Institute for Psychiatric Services
International Congress on Schizophrenia Research
National Academy of Medicine
National Academy of Sciences
Schizophrenia International Research Society
Singapore Psychiatric Association
South Africa Society of Biological Psychiatry
Spanish Psychiatric Association

Spanish-Polish Psychiatric Association
Winter Workshop on Schizophrenia Research
World Congress of Biological Psychiatry

CONFERENCE/WORKSHOP/SYMPOSIUM ORGANIZER:

Co-Chair, Symposium: Biomarkers of Treatment Response and Tolerability in Psychosis and Mood Disorders, American Psychiatric Association, May 2016.

Georgia Psychiatric Physicians Association Winter and Sumer CME Meetings - Twice annually, (2005-2016).

How can schizophrenia researchers change patient care in their health care systems? International Congress on Schizophrenia Research. Colorado Springs, Colorado, April 2011.

Science to Services: Progress in Schizophrenia research from around the globe. International Congress on Schizophrenia Research. San Diego, CA, April 2009.

Is AACDP on your mind? American Association of Chairs of Departments of Psychiatry Association. Amelia Island, Florida, August 2008.

Career development in psychiatry: what's in it for me? Annual meeting of the American Psychiatric Association, Washington DC, May 2008.

Am I a psychiatrist or an endocrinologist?: managing metabolic disturbance in schizophrenia. Annual meeting of the American Psychiatric Association, San Diego, May 2007.

When endocrinology and psychiatry collide: metabolic disturbances in schizophrenia. Annual meeting of the American Psychiatric Association, San Diego, May 2007.

Science to Services: Progress in schizophrenia research from around the globe. International Congress on Schizophrenia Research. Colorado Springs, Colorado, March 2007.

Substance abuse comorbidity in schizophrenia. CINP, Chicago, July 2006.

Verging on reality: emergent therapeutic approaches to schizophrenia. Annual meeting of the American Psychiatric Association, Toronto, Canada, May 2006.

Topical issues in the treatment of schizophrenia. 8th World Congress of Biological Psychiatry, Vienna, Austria, July 2005.

Science to Services: Progress in schizophrenia research from around the globe. Symposium at the Tenth International Congress on Schizophrenia Research, Savannah, Georgia, April 2005.

Choosing the right dose of an atypical antipsychotic: art or science? American Psychiatric Association Annual meeting, New York, May 2004.

The Neurobiology and management of violence and schizophrenia. Plenary session, 9th International Congress on Schizophrenia Research, Colorado Springs, Colorado, March 2003.

Violence and mental illness: assessment and effective interventions. Medical College of Georgia, Augusta, Georgia, September 2001.

Increased morbidity and mortality in schizophrenia. Royal College of Psychiatrists Annual Meeting, Edinburgh, Scotland, July 2000.

Co-morbid disease and mortality in schizophrenia. American Psychiatric Association 2000 Annual

Meeting, Chicago, Illinois, May 2000.

Schizophrenia: what do we know and how well are we applying it in clinical practice. Case Western Reserve University, Cleveland, Ohio, May 2000.

Continuity of care for schizophrenia: now more than ever. Case Western Reserve University, Cleveland, Ohio, April 1999.

Brain imaging in psychiatric adolescents: the sooner the better. Annual Meeting of the Society of Biological Psychiatry, Toronto, Ontario, May 1998.

Treatment guidelines and best practices for schizophrenia. Case Western Reserve University, Cleveland, Ohio, May 1998.

Brain imaging and serious mental illness: another look. All-Ohio Institute on Community Psychiatry, Cleveland, Ohio, October 1997.

Relatives, mental health professionals and advocacy: collaborations for success. Cleveland, Ohio, May 1997.

Mental illnesses are brain disorders: to biology and beyond. Case Western Reserve University, Cleveland, Ohio, May 1997.

Adolescent-onset psychosis: clues to the pathogenesis of schizophrenia. Symposium at the Sixth International Congress on Schizophrenia Research, Colorado Springs, Colorado, April 1997.

Mental health care and relatives: the major issues. Cleveland, Ohio, May 1996.

Doing the right thing well: optimizing medication and psychosocial therapies for the severely mentally ill. Case Western Reserve University, Cleveland, Ohio, May 1996.

New drug treatments for psychoses: new opportunities for public psychiatry. Symposium, All-Ohio Institute on Community Psychiatry, Cleveland, Ohio, March 1996.

Imaging of the "mind". Symposium, All-Ohio Institute on Community Psychiatry, Cleveland, Ohio, March 1996.

Diagnosis and treatment of psychotic disorders. Cleveland State University, Cleveland, Ohio, June 1995

Developments in mental health care: relatives' perspectives. Cleveland, Ohio, May 1995.

Innovations in mental health care in public psychiatry: opportunities and challenges. Case Western Reserve University, Cleveland, Ohio, May 1995.

Developmental neurobiology and mental illness: evolving perspectives. Symposium at All-Ohio Institute on Community Psychiatry, Cleveland, Ohio, March 1995.

PUBLICATIONS:

Books

1. Buckley PF, Bird J, Harrison G: Examination Notes in Psychiatry - Third Edition. Butterworth-Heinemann, 1995.
2. Waddington JL and Buckley PF: The Neurodevelopmental Basis of Schizophrenia. Landes Publications, Austin, Texas, 1996.

3. Buckley PF: Schizophrenia. Psychiatric Clinics of North America. Saunders Publications, Philadelphia, Pennsylvania, 1998.
4. Buckley PF: Sexuality and Serious Mental Illness. The Gordon and Breach Publishing Group, Newark, New Jersey, 1999.
5. Buckley PF, Waddington JL: Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Butterworth-Heinemann, 2000.
6. Buckley PF. Schizophrenia: Contemporary Perspectives. Psychiatric Clinics of North America. W.B. Saunders, Philadelphia, 2003.
7. Jones P, Buckley PF: Schizophrenia. Blackwell Publications 2003.
8. Buckley PF, Prewette D, Bird J, Harrison G. Examination Notes in Psychiatry, Fourth Edition, Hodder Publications, 2005.
9. Jones P, Buckley PF. In Clinical Practice: Schizophrenia. Elsevier 2006.
10. Buckley PF, Messias E. Schizophrenia: A complex disease necessitating complex care. Psychiatric Clinics of North America, Saunders Publications, Philadelphia, Pennsylvania, 2007.
11. Wilson DR, Buckley PF. Administrative Psychiatry, Psychiatric Clinics of North America. Saunders Publications, Philadelphia, Pennsylvania, 2008.
12. Castle D, Buckley PF. Schizophrenia. Oxford University Press, London, England, 2008.
13. Buckley PF, Foster A, Patel N, Weimert S. Adherence to Mental Health Treatment. Oxford University Press, Cambridge, MA, 2009.
14. Buckley PF. Schizophrenia. Psychiatric Clinics of North America. Saunders Publications, Philadelphia, Pennsylvania, 2012.
15. Buckley PF, Gaughran F. Treatment – Refractory Schizophrenia: A Clinical Conundrum. Springer-Verlag Berlin Heidelberg, 2014.
16. Castle D, Buckley PF. Schizophrenia. Oxford University Press, London, England, 2015.
17. Buckley PF. Mental Health in the Medical Setting: Service Delivery, Workforce Needs, and Emerging Best Practices. Psychiatric Clinics of North America, 2015.
18. Buckley PF. Schizophrenia: Advances and Current Management. Psychiatric Clinics of North America, 2016.
19. Castle D, Gaughran F, Buckley P. Physical Health and Schizophrenia. Oxford University Press, 2017.
20. Castle D, Buckley P, Goldsworthy R. Schizophrenia and Psychiatric Comorbidity. Oxford University Press, London England, 2020.

Book Chapters and Monographs

1. Buckley PF, Meltzer HY: Treatment of schizophrenia. In: Textbook of Psychopharmacology, Edited by AF Schatzberg and CB Nemeroff. American Psychiatric Press, Washington, DC, 1995.
2. Waddington JL, O'Callaghan E, Youssef HA, Buckley PF, Lane A, Cotter D, Larkin C: The neurodevelopmental basis to schizophrenia: beyond a hypothesis. In: Schizophrenia - An Integrated View, Edited by R Fog, J Gerlach, P Hemmingsen, Krogsgaard-Larsen, JH Thaysen. Copenhagen, Munksgaard, 1995.

3. Schulz SC, Buckley PF: Treatment resistant schizophrenia. In: Schizophrenia, Edited by SR Hirsch and DR Weinberger, Blackwell Publications, 1995.
4. Waddington JL, O'Callaghan E, Buckley P, Madigan C, Larkin C, Redmond O, Stack JP, Ennis JT, Kinsella A: Vulnerability to tardive dyskinesia in schizophrenia: an exploration of individual patient factors. In: Neuroleptic Induced Movement Disorders: A Comprehensive Survey, Edited by R Yassa, DR Nair, D Jeste, 1995.
5. Waddington JL, Buckley PF: Neurodevelopment and schizophrenia: a role of active progression? In: The Neurodevelopmental Basis of Schizophrenia, Edited by JL Waddington and PF Buckley. Landes Publications, Austin, Texas, 1996.
6. Buckley PF, Larkin C, Friedman L, Lewin JS, Waddington JL: Neurodevelopmental pathobiology of schizophrenia: functional correlates of magnetic resonance spectroscopy and fast MRI. In: The Neurodevelopmental Basis of Schizophrenia, Edited by JL Waddington and PF Buckley. Landes Publications, Austin, Texas, 1996.
7. Buckley PF, Meltzer HY: Schizophrenia and the organic psychoses. In: Current Practice of Medicine, Neurology/Psychiatry volume, Edited by J. Fawcett. Current Practice of Medicine, Philadelphia, 1996.
8. Waddington JL, O'Callaghan E, Buckley PF, Larkin C: Structural brain imaging and schizophrenia in a neurodevelopmental context. In: The Neurodevelopmental Basis of Schizophrenia, Edited by JL Waddington and PF Buckley. Landes Publications, Austin, Texas, 1996.
9. Buckley P, Schulz SC. Treatment of acute psychosis. In: Clinical Simulations in the Management of Psychotic Disorders. 3rd Edition, 1998.
10. Waddington JL, O'Callaghan E, Youssef HA, Buckley P, Lane A, Cotter D, Larkin C: Schizophrenia: Evidence for a "cascade" process with neurodevelopmental origins. In: Prenatal Exposures in Schizophrenia, Edited by ES Susser, AS Brown, JM Gorman. American Psychiatric Press, Inc., Washington, D.C., 1999.
11. Waddington JL, O' Callaghan E, Youssef HA, Buckley PF, Madigan C, Larkin C, Kinsella A: Clinical correlates of tardive dyskinesia. In: Chronic Schizophrenia and the Search for Antecedents in the Disease Process. Edited by S Szymanski, J Kane, D Casey.
12. Dean D, Buckley P, Bookstein F, Kamath J, Kwon D, Friedman L, Lys C: Three dimensional MR- based morphometric comparison of schizophrenic and normal cerebral ventricles. In: Lecture Notes in Computer Science. Edited by K-H. Hohne. Springer-Verlag, 1996.
13. Dean D, Subramanyan K, Kamath J, Bookstein FL, Wilson D, Kwon D, Buckley P: Comparison of traditional brain segmentation tools with 3D self-organizing maps. In: Lecture Notes in Computer Science. Edited by K-H. Hohne. Springer-Verlag, 1997.
14. Buckley PF, Robben T, Friedman L, Hyde J: Sexual behavior in persons with serious mental illness: patterns and clinical correlates. In: Sexuality and Serious Mental Illness. Edited by PF Buckley. The Gordon and Breach Publishing Group, Newark, New Jersey, 1999.
15. Buckley PF, Hogan M, Svendsen DP, Gintoli G: Dilemmas of managing sexual activity among psychiatric inpatients. In: Sexuality and Serious Mental Illness. Edited by PF Buckley. The Gordon and Breach Publishing Group, Newark, New Jersey, 1999.
16. Buckley PF, Gutheil TG. Sexuality, stigma busting and mental illness. In: Sexuality and Serious Mental Illness. Edited by PF Buckley. The Gordon and Breach Publishing Group, Newark, New Jersey, 1999.
17. Buckley PF: Structural brain imaging in schizophrenia. In: Schizophrenia. Edited by PF Buckley.

- Psychiatric Clinics of North America. Saunders Publications, Philadelphia, Pennsylvania, 1998.
18. Buckley PF, Dayem M: Schizophrenia. In: Current Practice of Medicine, Second Edition. Edited by R. Hales. (Fitzgerald F, series ed.) Current Medicine, Philadelphia, Pennsylvania, 1999.
 19. Roth B, Buckley PF, Schulz SC: Molecular biology and antipsychotic medications. In: Schizophrenia in a Molecular Age. Edited by CA Tamminga. (Review of Psychiatry Series; Oldham JO and Riba MB, series eds.) American Psychiatric Press, Inc., Washington, D.C., 1999.
 20. Buckley PF, Naber D: Quetiapine and sertindole: clinical use and experience. In: Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Edited by PF Buckley and JL Waddington. Butterworth-Heinemann, 2000.
 21. Taylor P, Buckley PF: Management of aggression in schizophrenia. In: Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Edited by PF Buckley and JL Waddington. Butterworth-Heinemann, 2000.
 22. Buckley PF, Sajatovic M, Adityanjee: Neuroleptic malignant syndrome. In: Neuromuscular Disorders in Clinical Practice. Edited by B Katiri, HJ Kaminski, DC Preston, RL Ruffs, BE Shapiro. Butterworth-Heinemann, 2001.
 23. Buckley PF: Endocrine and metabolic effects of typical and atypical antipsychotics: contemporary clinical experience. In: Managing the Side Effects of Drug Therapy in Schizophrenia. Edited by Kane JM. Science Press Limited, London, 1999.
 24. Barnes TRE, Buckley PF, Schulz SC: Treatment-resistant schizophrenia. In: Schizophrenia. Second Edition. Edited by SR Hirsch and DR Weinberger. Blackwell Publishing: Oxford, 2003, pp. 489- 516.
 25. Buckley PF, Noffsinger SC, Smith D, Hrouda D, Knoll J. Violence and Schizophrenia. In: Schizophrenia: Contemporary perspectives. Edited by PF Buckley. WB Saunders, Philadelphia (2003).
 26. Londino D, Dallas D, Buckley PF. Use of atypical antipsychotic medications in children and adolescents. In: Atypical antipsychotics in clinical practice, from bench to bedside. Edited by JL Lauriello, J. Csernansky; Marcell Denker Inc., New York 2004.
 27. Crismon ML, Buckley PF. Schizophrenia. In: Pharmacotherapy: a pathophysiologic approach. Sixth Edition. Edited by Dipiro J, Talbert RL, Yee GL, Matzke GR, Wells BG, Posey LM. McGraw- Hill, New York, 2005.
 28. Mahadik SP, Buckley PF. Psychotropic agents, oxidative stress, and schizophrenia. In: Fatty acids and oxidative stress in neuropsychiatric disorders. Reddy N, Yao I, editors 2007.
 29. Mahadik SP, Evans D, Shendarkar N, Narasimhan M, Buckley PF. Can augmentation with omega- 3 fatty acids and antioxidant supplementation enhance antipsychotic treatment response in schizophrenia? In: Fatty acids and oxidative stress in neuropsychiatric disorders. Reddy N, Yao I, editors, 2007.
 30. Foster A, Buckley PF. Schizophrenia. In: Conn's Textbook of Medicine. McGraw-Hill, 2007.
 31. Nichita C, Buckley PF. Comorbidities of antisocial personality disorder. In: International Handbook of Psychopathy. Felthous A, Taylor P (editors), 2008.
 32. Foster A, Miller DD, Buckley PF. Pharmacogenetics of schizophrenia. In: Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America 2007.
 33. Weiden PF, Buckley PF, Crody M, Evans D, Understanding and treating first episode schizophrenia. In:

- Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America, 2007.
34. Peebles S, Davidson L, Mabe A, Fenley G, Buckley PF. Recovery and schizophrenia. In: Schizophrenia: a complex disorder necessitating comprehensive care. Buckley PF, Messias E (editors) Psychiatric Clinics of North America, 2007.
 35. Buckley PF, Foster A. Quetiapine. In: A Textbook of Psychopharmacology, Schatzberg AF, Nemeroff CB (editors), American Psychiatric Association 2009.
 36. Crismon L, Buckley PF. Schizophrenia. In: Pharmacotherapy: a pathophysiological approach, Seventh Edition. Edited by Depiro J, Talbert RL, Yee GL, Matzke GR, Wells BG, Posey LM. McGraw-Hill. New York, 2008.
 37. Nichita C, Buckley PF. Management of aggression. In: Forensic Psychiatry. Edited by P. Taylor 2013.
 38. Buckley PF, Madaan, V. Professional and Leadership Development. In: Administrative Psychiatry. Wilson DR, Buckley PF. Psychiatric Clinics of North America 2008
 39. Buckley, PF, Miller B. Treatment of first episode schizophrenia. In: Schizophrenia, Edited by S. Kasper 2009.
 40. Jones, PJ, Buckley PF. Schizophrenia and related psychoses. In: Handbook for MRPsych. Edited by S. Puri. Hodder publications, 2010.
 41. Miller B, Buckley PF. Schizophrenia. In: Conn's Textbook of Medicine. McGraw-Hill, 2009.
 42. Buckley PF, Meyer J. Substance abuse comorbidity and schizophrenia. In: Medical comorbidities in schizophrenia., Nasrallah HA, Meyer J (editors), American Psychiatric Association 2009.
 43. L Coleman, T, Buckley PF, Fincher R. Fostering the Professional Development of Medical Education Leaders. In: Leadership Careers in Medical Education. Pangaro L (ed) ACP Press. American College of Physicians, Philadelphia, 2010; 73-100.
 44. Buckley, PF, Foster A, Miller D. Pharmacogenomics of schizophrenia. In: Pharmacogenomics in Psychiatry. Schwab, M (ed). "Advances in Biological Psychiatry" book series, 2010.
 45. Ahmed AO, Mabe PA, & Buckley PF. Recovery in schizophrenia: Perspectives, evidence, and implications. In Handbook of Schizophrenia Spectrum Disorders (Vol. III): Therapeutic Approaches Comorbidity and Outcomes. M.S. Ritsner (Ed.). New York: Springer. 2011;1-22).
 46. Buckley PF, Foster A, Van Sant S. Schizophrenia. In: International Handbook of Psychiatry. A concise guide for medical students, residents, and medical practitioners. Edited by Roberts L, Leyde J, Balon R. World Scientific. New Jersey, 2013.
 47. Mortimer A, Buckley PF. Schizophrenia, therapeutic strategies for non responders. In: Therapeutic Strategies in Schizophrenia, Mortimer A, (ed) Nova Publication. London, England, 2011.
 48. Crismon L, Argo T, Buckley PF. Schizophrenia: a pathophysiological approach, Eighth Edition. Edited by: Depiro J, Talbert RL, Yee GL, Motzke GR, Wells BG, Posey LM. McGraw-Hill, New York, 2011.
 49. Souza JS, Karo M, Neto JH, Elkis H, Buckley PF. New therapeutic strategies for resistance to clozapine and treatment resistant schizophrenia. In: Schizophrenia. Elkis H et al (eds). Kariger, Barel Switzerland 2011.
 50. Foster A, Miller DD, Buckley PF. Pharmacogenetics and schizophrenia. In: Clinics in Laboratory Medicine, Genetics and Neurological and Psychiatric Diseases. WB Saunders, Philadelphia, 2010; 975-993.

51. Miller B, Buckley PF. Schizophrenia. In: Conn's Textbook of Medicine. McGraw-Hill, 2012; pp. 962-965.
52. Buckley PF, Ahmed AO. Principles and practices of medication management for people with schizophrenia: evolution within a recovery-based framework of care. In: Yeager K, Cutler D, Svendsen D, Sills G (eds.), *Modern Community Mental Health: An Interdisciplinary Approach*. New York: Oxford University Press, 2013.
53. Ahmed MO, Fridberg D, Hanna M, Buckley PF. Brain-Derived Neurotrophic Factor and neurocognitive profiles in the psychosis spectrum: findings in bipolar disorder and schizophrenia. In: Moore NB (eds.), *Bipolar Disorders: Symptoms, Management, and Risk Factors*. New York: Nova Science Publishers, 2013.
54. Buckley, PF, Foster A, Byerly M. Quetiapine. In: *A Textbook of Psychopharmacology*; Schatzberg AF, Nemeroff CB (editors), American Psychiatric Association, 2013.
55. Buckley PF, Foster A, Van Sant S., Freudenrich D. Iloperidone. In: *A Textbook of Psychopharmacology*, Schatzberg AF, Nemeroff CB (editors), American Psychiatric Association, 2013.
56. Adityanjee, Buckley PF, Sajatovic M: Neuroleptic malignant syndrome. In: *Neuromuscular Disorders in Clinical Practice. Second Edition*. Edited by B Katiri, HJ Kaminski, DC Preston, RL Ruffs, BE Shapiro. Butterworth-Heinemann, 2015.
57. Buckley PF, Ahmed A. Principles and Practices of Medication Treatments: Evolution within a Recovery-Based Framework of Care. In: 'A Textbook of Modern Community Mental Health Work: An Interdisciplinary Approach.' Cutler D, Svendsen D (editors), 2013.
58. P. Buckley. Antipsychotic Polypharmacy - secret source or 'wild abandon'? In: *Polypharmacy in Psychiatry Practice*. M. Ritsner (ed), 2013.
59. Miller B, Buckley PF. Schizophrenia. In: *Conn's Textbook of Medicine*. McGraw-Hill. 2013.
60. Ahmed AO, Doane NJ, Mabe PA, Buckley PF, Brigenheir D, Goodrum NM. Peers and Peer-Led Interventions for People with Schizophrenia. *Psychiatric Clinics of North America*, 2012.
61. Pillai A, Buckley PF. Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. *Psychiatric Clinics of North America*, 2012.
62. Crismon L, Argo T, Buckley PF. Schizophrenia: a pathophysiological approach, Eighth Edition. Edited by: Depiro J, Talbert RL, Yee GL, Motzke GR, Wells BG, Posey LM. McGraw-Hill, New York, 2014.
63. Elkis H, Buckley PF. Biology of schizophrenia: Is treatment-refractoriness synonymous with severity of illness [A.D.A. Is this a drug-efficacy problem or an expression of severe illness?]. In: *Treatment Refractory Schizophrenia: A Clinical Conundrum*. Edited by Buckley PF, Gaughran F. Springer, 2014.
64. Miller B, Buckley PF. Medical and psychiatric comorbidities: Complicating treatment expectations. In: *Treatment Refractory Schizophrenia: A Clinical Conundrum*. Edited by Buckley PF, Gaughran F. Springer, 2014.
65. Buckley PF, Foster A. Schizophrenia. In: *Metabolism of Human Disease: Organ Physiology and Pathophysiology*. Edited by Zeeb M (Editor). Springer, 2014.
66. Buckley PF, Hwang M. Comorbid psychiatric disorders in schizophrenia. In: Zink M, de Hoan L, Schoirmbeck F. (Editors), *Obsessive Compulsive Symptoms in Schizophrenia*. Springer, 2015.
67. Vitacco, M.J., & Neumann, C.S., Welch, L., & Buckley, P. Clinical assessment of psychopathy. In R. Jackson (Ed.), *Teaching Forensic Assessment*, 2nd Edition. San Francisco, CA: Lawrence Erlbaum.

2015.

68. Miller BJ, Buckley PF: Schizophrenia. In Bope, Rakel, Kellerman (eds): Conn's Current Therapy, 2014 edition. Philadelphia: Saunders, 2014.
69. Buckley PF, Miller B. Schizophrenia: a progress report. In: Year End Report. Psychiatric Clinics of North America, Edited by David Baron, 2015; 38(3):373-377.
70. Miller BJ, Buckley PF: Schizophrenia. In Bope, Rakel, Kellerman (eds): Conn's Current Therapy, 2015 edition. Philadelphia: Saunders, 2015, pp. 995-998.
71. Buckley, PF, Foster A, Byerly M. Quetiapine. In: A Textbook of Psychopharmacology; Schatzberg AF, Nemeroff CB (editors), American Psychiatric Publishing, 2017.
72. Buckley PF, Foster A, Van Sant S., Freudenrich D. Iloperidone. In: A Textbook of Psychopharmacology, Schatzberg AF, Nemeroff CB (editors), American Psychiatric Publication, 2017.
73. Crismon L, Argo T, Buckley PF. Schizophrenia: a pathophysiological approach, Eighth Edition. Edited by: Depiro J, Talbert RL, Yee GL, Motzke GR, Wells BG, Posey LM. McGraw-Hill, New York, 2017.
74. Elkis H, Buckley PF. Treatment-resistant schizophrenia. In: Schizophrenia-Advances and Current Management. Psychiatric Clinics of North America, Edited by Buckley P. 2016.
75. Miller BJ, Buckley PF. The case for adjunctive monoclonal antibody immunotherapy in schizophrenia. In: Schizophrenia-Advances and Current Management. Psychiatric Clinics of North America, Edited by Buckley P. 2016.
76. Ahmed AO, Marino BA, Rosenthal E, Buckner A, Hunter KM, Mabe PA, Buckley PF. Recovery in schizophrenia: what consumers know and that know. In: Schizophrenia-Advances and Current Management. Psychiatric Clinics of North America, Edited by Buckley P. 2016.
77. Nichita EC, Buckley PF. Comorbidities of psychopathy and antisocial personality disorder: prevalence and implications. In: The Wiley International Handbook of Psychopathic Disorders and the Law, Second Edition. Edited by: Felthous AR, Sass H, 2016.
78. Miller B, Buckley PF. Schizophrenia. In: Conn's Textbook of Medicine. McGraw-Hill, 2017.
79. Buckley PF, Miller B. Psychosis in general medical conditions, organic brain disorders, cardiovascular disorders. In: Psychosis. Edited by: Tamminga CA, Van Os J, Ivleva EI, Reininghaus U. Oxford University Press, 2020.
80. Pandurangi A, Buckley PF. Anti-inflammatory drugs as treatments for schizophrenia. In: Neuroinflammation and Schizophrenia. Edited by Khandaker, Meyer, Jones P. Springer Publishers.
81. Miller B, Buckley PF. Schizophrenia. In: Conn's Current Therapy, 2019.
82. Crismon L, Smith T, Buckley PF. Schizophrenia: a pathophysiological approach. Edited by: Depiro J, Talbert RL, Yee GL, Motzke GR, Ellingrod V, Posey LM. McGraw-Hill, New York, 2019.
83. Woleben C, Buckley PF. Trainee Empathy: blending traditional and novel influences. In teaching empathy in Healthcare: building a new core competency, Foster A, Yaseen Z, editors, Springer, 2019.
84. Miller B, Buckley PF. Schizophrenia. In: Conn's Current Therapy, 2020.
85. Buckley, PF, Foster A, Quetiapine. In: A Textbook of Psychopharmacology; Schatzberg AF, Nemeroff CB (editors), American Psychiatric Publishing, for publication in 2022.
86. Buckley PF, Foster A. Iloperidone. In: A Textbook of Psychopharmacology, Schatzberg AF, Nemeroff CB (editors), American Psychiatric Publication, for publication in 2022.

87. Crismon L, Smith T, Buckley PF. Schizophrenia: a pathophysiological approach, Twelfth Edition. Edited by: Depiro J, Talbert RL, Yee GL, Motzke GR, Ellingrod V, Posey LM. McGraw-Hill, New York, for publication in 2022.
88. Townsend L, Buckley PF. Companion animals in the treatment of serious mental illness. In: The role of companion animals in the treatment of mental disorders. Edited by Gee N, Townsend L, Findling RF. American Psychiatric Association, for publication in 2022.

Peer Reviewed Manuscripts

1. Carmody E, Buckley PF, Hutchinson M: Brainstem infarction following chiropractic manipulation. Irish Medical Journal 1987; 80: 295-296.
2. Buckley PF, Walshe D, Colohan H, O'Callaghan E, Mulvany F, Gibson T, Larkin C, Waddington JL: Violence and schizophrenia - a study of the occurrence and clinical correlates of violence among schizophrenic patients. Irish Journal of Psychological Medicine 1990; 7: 102-108.
3. Buckley PF, Carmody E, Hutchinson M: Wilson's disease and the neuroleptic malignant syndrome. Irish Journal of Psychological Medicine 1990; 7: 138-139.
4. Buckley PF, Larkin C, O'Callaghan E: Psychosis following use of proprietary antidiarrhoea medicines. British Journal of Psychiatry 1990; 157: 758-759.
5. Buckley PF, Cannon M, Larkin C: Abuse of neuroleptic drugs. British Journal of Addiction 1991; 86: 789-790.
6. Cannon M, Buckley PF, Larkin C: Suicide in schizophrenia. Irish Journal of Psychological Medicine 1991; 8: 19-22.
7. O'Callaghan E, Gibson T, Colohan H, Walshe D, Buckley PF, Larkin C, Waddington JL: Season of birth in schizophrenia: confinement of winter birth excess to patients without a family history. British Journal of Psychiatry 1991; 158: 764-769.
8. Buckley P, Freyne A, McCarthy A, Larkin C: Neuroleptic malignant syndrome - a follow-up study. Irish Journal of Medical Science 1991; 160, 2: 45-47.
9. Buckley PF, Freyne A, Walsh N: Anorexia nervosa in males. Irish Journal of Psychological Medicine 1991; 8: 15-18.
10. Buckley PF, Cambell A: Feigned psychosis. Irish Journal of Psychological Medicine 1991; 8: 48-50.
11. Waddington JL, O'Callaghan E, Buckley PF, Larkin C, Redmond O, Stack J, Ennis JT: The age-dependencies of MRI abnormalities in schizophrenia suggest early ventricular enlargement but later prominence of cortical atrophy. Schizophrenia Research 1991; 5, 188-189.
12. O'Callaghan E, Buckley PF, Redmond O, Stack J, Ennis JT, Waddington JL: Abnormalities of cerebral structure in schizophrenia on magnetic resonance imaging: interpretation in relation to the neurodevelopmental hypothesis. Journal of the Royal Society of Medicine 1992; 15: 306-309.
13. Freyne A, Buckley PF, Larkin C, Walsh N: Consultation-liaison psychiatry within the general hospital: Referral pattern and management. Irish Medical Journal 1992; 85: 112-115.
14. Buckley PF, O'Callaghan E, Larkin C, Redmond O, Stack J, Ennis JT, Waddington JL: Cerebral pathology, MRI, and schizophrenia. Biological Psychiatry 1992; 15: 209-210.
15. Buckley PF, O'Callaghan E, Larkin C, Waddington JL: Editorial: Schizophrenia research: the problem of

- controls. *Biological Psychiatry* 1992; 32: 215-217.
16. O'Callaghan E, Gibson T, Colohan H, Walshe D, Buckley PF, Larkin C, Waddington JL: Risk of schizophrenia in adults born after obstetric complications and the association with early onset of illness: a controlled study. *British Medical Journal* 1992; 305: 1256-1259.
 17. Buckley PF, Stack JP, Madigan C, O'Callaghan E, Larkin C, Redmond O, Ennis JT, Waddington JL: Evaluation by magnetic resonance imaging of the schizophrenia-like psychoses associated with cerebral trauma: clinico-pathological correlates. *American Journal of Psychiatry* 1993; 150: 146-148.
 18. Hagger C, Buckley PF, Kenny JT, Friedman L, Ubogy D, Meltzer HY: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. *Biological Psychiatry* 1993; 34: 702-712.
 19. Buckley PF and Hutchinson M: Psychosis and multiple sclerosis. *British Journal of Psychiatry* 1993; 162: 422-423.
 20. O'Callaghan E, Gibson T, Colohan H, Walshe D, Buckley PF, Larkin C, Waddington JL: Obstetric complications and schizophrenia. *British Medical Journal* 1993; 306: 268-269.
 21. Buckley PF, Meltzer HY: Clozapine and NMS. *British Journal of Psychiatry*. 1993; 162: 566.
 22. Buckley PF: Neuroradiological anomalies and schizophrenia. *Journal of Neurology, Neurosurgery and Psychiatry* 1993.
 23. Buckley PF: 'Functional psychoses- is the concept disintegrating?' *Psychosomatics* 1993; 34: 462.
 24. Lai S, Hopkins A, Haacke M, Buckley PF, Friedman L, Meltzer HY, Wasserman B, Hedera P, Friedland B: High resolution 2D and 3D functional activation imaging at 1.5T: preliminary results. *Magnetic Resonance in Medicine* 1993; 30: 387-392.
 25. Hutchinson M, Stack JP, Buckley PF: Bipolar affective disorder prior to the onset of multiple sclerosis. *Acta Neurologica Scandinavica* 1993; 6: 388-393.
 26. Buckley PF: Current approaches to the management of schizophrenia. *Irish Doctor* 1993; 10: 18-23.
 27. Buckley PF: Magnetic resonance imaging of the 'mind': implications for psychiatry. *Imaging* 1993; 50: 213-222.
 28. Buckley PF, Thompson P, Way L, Meltzer HY: Substance abuse among patients with treatment resistant schizophrenia: characteristics and implications for clozapine therapy. *American Journal of Psychiatry* 1994; 151: 354-359.
 29. Buckley PF, O'Donovan CA: Cerebral asymmetry, planum temporale and aberrant neurodevelopment in schizophrenia. *Archives of Neurology* 1994; 51: 540.
 30. Buckley PF, Sajatovic M, Meltzer HY: Treatment of delusional disorders with clozapine. *American Journal of Psychiatry* 1994; 151: 1394-1395.
 31. Haacke M, Hopkins A, Lai S, Friedman L, Meltzer HY, Hedera P, Friedland B, Klein S, Thompson P, Detterman D, Tkach J, Lewin J, Buckley PF: 2D and 3D high resolution gradient echo functional imaging of the brain: initial methodology and experience with motor cortex, visual cortex, and cognitive studies. *NMR in Biomedicine* 1994; 7: 54-62.
 32. Thompson PA, Buckley PF, Meltzer HY: The Brief Psychiatric Rating Scale: effect of scaling system on clinical response assessment. *Journal of Clinical Psychopharmacology* 1994; 14: 344-346.
 33. Buckley PF, Freyne A, Walsh N: The medical-psychiatry unit: A European experience. *Psychosomatics*

- 1994; 35: 515-519.
34. Buckley PF, Moore C, Long H, Larkin C, Thompson P, Mulvany F, Redmond O, Stack JP, Ennis JT, Waddington JL: ¹H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental and cognitive correlates. *Biological Psychiatry* 1994; 36(12): 792-800.
 35. Buckley PF: Dualism in psychiatry. *Lancet* 1994; 354: 1102.
 36. Buckley PF, Schulz SC: Obsessive compulsive symptoms with clozapine. *British Journal of Psychiatry* 1994; 165: 408.
 37. Buckley PF, Thompson PA, Way L, Meltzer HY: Substance abuse and clozapine treatment. *Journal of Clinical Psychiatry* 1994; 55(B): 114-116.
 38. Buckley PF, Waddington JL: Editorial: Magnetic resonance spectroscopy in schizophrenia: a nascent technology for a neurodevelopmental disorder? *Biological Psychiatry* 1994; 36(12): 789- 791.
 39. O'Callaghan E, Buckley PF, Madigan C, Redmond O, Stack JP, Kinsella A, Larkin C, Ennis JT, Waddington JL: The relationship of minor physical anomalies and other putative indices of developmental disturbance in schizophrenia to abnormalities of cerebral structure on MRI. *Biological Psychiatry* 1995; 38:516-24.
 40. Maes M, Meltzer HY, Buckley PF, Bosmans E: Plasma-soluble interleukin-2 and transferin receptor in schizophrenia and major depression. *European Archives of Psychiatry and Clinical Neuroscience* 1995; 244: 325-329.
 41. Buckley PF, O'Callaghan E, Mulvany F, Larkin C, Stack JP, Redmond O, Ennis JT, Waddington JL: Basal ganglia T₂ relaxation times in schizophrenia: A quantitative magnetic resonance imaging study. *Psychiatry Research Neuroimaging* 1995; 61(2): 95-102.
 42. Buckley PF, Hutchinson M: Editorial: Neuroleptic malignant syndrome. *Journal of Neurology, Neurosurgery and Psychiatry* 1995; 58: 271-273.
 43. Buckley PF, Kausch O, Gardner G: Clozapine treatment of schizophrenia: implications for forensic psychiatry. *Journal of Clinical Forensic Medicine* 1995; 2: 9-16.
 44. Waddington JL, O'Callaghan E, Buckley PF, Madigan C, Redmond O, Stack JP, Kinsella A, Larkin C, Ennis JT: Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on MRI. *British Journal of Psychiatry* 1995; 167: 41-44.
 45. Buckley PF, Bartell JA, Donenwirth K, Lee S, Torigoe F, Schulz SC: Violence and schizophrenia: clozapine as a specific anti-aggressive agent. *Bulletin of the American Academy of Psychiatry and the Law* 1995; 23: 607-11.
 46. Buckley PF, Buchanan RW: Catching up on schizophrenia. *Archives of General Psychiatry* 1996; 53: 456-462.
 47. Mishara A, Orr B, Buckley PF: Staff attitudes to clozapine therapy: initial observations. *Journal of Psychosocial Nursing* 1995; 33: 44-47.
 48. Buckley PF: Novel antipsychotics and NMS. *Psychiatric Services* 1996; 47:431.
 49. Buckley PF: Clozapine treatment of schizophrenia. *Irish Journal of Psychiatry* 1994; 15: 3-9.
 50. Elkis H, Friedman L, Buckley PF, Lee HS, Lys C, Kaufman B, Meltzer HY: Increased prefrontal sulcal prominence in relatively young patients with unipolar major depression. *Psychiatry Research: Neuroimaging* 1996; 67: 123-134.

51. Buckley PF, Donenwirth K, Bayer KE, Lys C, Ibrahim ZY, Schulz SC: Risperidone for treatment- resistant schizophrenia: Initial clinical experience in a state hospital. *Pharmacy Technology* 1996; 12: 271-275.
52. Buckley PF, Lys C: Psychotherapy and schizophrenia. *The Journal of Psychotherapy Practice and Research* 1996; 5: 185-201.
53. Buckley PF, Friedman L, Wu D, Lai S, Meltzer HY, Haacke EM, Miller D, Lewin JS: Functional magnetic resonance imaging in schizophrenia: initial methodology and evaluation of the motor cortex. *Psychiatry Research: Neuroimaging* 1997; 74: 13-23.
54. Buckley PF, Cola P, Hasegawa M, Lys C, Thompson P: Clozapine plasma levels and dosing strategies in treatment-refractory schizophrenic patients. *Irish Journal of Psychological Medicine* 1997; 14: 85-88.
55. Lewin JS, Friedman L, Wu D, Miller DA, Thompson LA, Klein SK, Wise AL, Hedera P, Buckley PF, Friedland RP, Meltzer HY: Cortical localization of human sustained attention: detection with functional MR using a visual vigilance paradigm. *Journal of Computer Assisted Tomography* 1996; 20: 695-701.
56. Buckley PF, Schulz SC: Clozapine and risperidone: refining and extending their use. *Harvard Review of Psychiatry* 1996; 4: 184-199.
57. Buckley PF: Treatment of schizophrenia: some advances in the decade of the brain. *British Journal of Hospital Medicine* 1996; 56: 575-581.
58. Buckley PF, Hyde JL: State hospital's responses to the sexual behavior of psychiatric inpatients. *Psychiatric Services* 1997; 48: 398-399.
59. Buckley PF, Gardner G, Lee S, Torigoe F: Clozapine treatment of sexual exhibitionism in schizophrenia. *Bulletin American Academy of Psychiatry and the Law* 1996; 24: 419-422.
60. Buckley PF, Ibrahim ZY, Singer B, Orr B, Donenwirth K, Brar PS: Aggression and schizophrenia: efficacy of risperidone. *Journal of the American Academy of Psychiatry and the Law* 1997; 25: 173-181.
61. Waddington JL, Buckley PF, Scully PJ, Lane A, O'Callaghan E, Larkin C. Course of psychopathology, cognition and neurobiological abnormality in schizophrenia: developmental origins and amelioration by antipsychotics? *Journal of Psychiatric Research* 1998; 32: 179-189.
62. Buckley PF, Hyde J, Winterich D: Sexual behavior and schizophrenia. *Canadian Journal of Psychiatry* 1996; 41: 603.
63. Buckley PF, Friedman L, Dean D: Brain imaging in schizophrenia: findings suggestive of a neurological disorder. *Imaging* 1997; 9: 39-47.
64. Buckley PF: New dimensions in the pharmacological treatment of schizophrenia and related psychoses. *Journal of Clinical Pharmacology* 1997; 37: 363-369.
65. Imbornoni S, Donenwirth K, Orr B, Hagesfeld, T, Gintoli G, Buckley PF: Objective measurement of psychiatric symptoms: A quality improvement process for inpatient care. *Joint Commission Journal on Quality Improvement* 1997; 23: 183-195.
66. Buckley, PF: The clinical stigmata of aberrant neurodevelopment in schizophrenia. *Journal of Nervous and Mental Diseases* 1998; 186: 79-86.
67. Buckley PF: Novel antipsychotic medications and the treatment of co-morbid substance abuse in schizophrenia. *Journal of Substance Abuse Treatment* 1998; 15: 113-116.
68. Hasan S, Buckley PF: Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. *American Journal of Psychiatry* 1998; 155: 1113-1116.

69. Buckley PF, Dean D, Friedman L, Kwon D, Bookstein FL, Lewin JS, Kamath J, Lys C: 3-Dimensional MR-based morphometrics and ventricular dysmorphology in schizophrenia. *Biological Psychiatry* 1999; 45: 62-67.
70. Buchanan B, Buckley PF, Tamminga CA, Schulz SC: Schizophrenia research: a biennium of progress. *Schizophrenia Bulletin* 1998; 24: 501-518.
71. Pinals DA, Buckley PF: Novel antipsychotic agents and their implications for forensic psychiatry. *Journal of the American Academy of Psychiatry and the Law* 1999; 27: 7-22.
72. Buckley PF: Novel antipsychotics and patient care in state hospitals. *Annals of Pharmacotherapy* 1998; 32: 906-914.
73. Buckley PF: Treatment of schizophrenia: let's talk dollars and sense. *American Journal of Managed Care* 1998; 4: 369-383.
74. Buckley PF, Hasan S: "Atypical" neuroleptic malignant syndrome and "atypical" antipsychotics. *American Journal of Psychiatry* 1998; 155: 1633.
75. Buckley PF: Substance abuse and schizophrenia - a review. *Journal of Clinical Psychiatry* 1998; 59(3): 26-30.
76. Buckley PF: New antipsychotic agents: emerging clinical profiles. *Journal of Clinical Psychiatry* 1999; 60(1): 12-17.
77. Buckley PF: Management of aggression in patients with schizophrenia. *Schizophrenia Monitor* 1998; 8: 19-22.
78. Buckley PF: How effective are the second generation antipsychotics?. *International Journal of Psychiatry in Clinical Practice* 1998; 2: 41-48.
79. Buckley PF, Wiechers IR: Sexual behavior of psychiatric inpatients: hospital responses and policy formulation. *Community Mental Health Journal* 1999; 35: 531-536.
80. Buckley PF, Robben T: A content analysis of state hospital policies on inpatient sexuality. *Psychiatric Services* 2000; 51: 243-245.
81. Buckley PF, Friedman L: Magnetic resonance spectroscopy: bridging the neurochemistry and neuroanatomy of schizophrenia. *British Journal of Psychiatry* 2000; 176: 203-205.
82. Friedman L, Wiechers IR, Cerny CA, Schulz SC, Buckley PF: If patients with schizophrenia have small brains, why don't they have small heads? *Schizophrenia Research* 2000; 42 (1): 1-6.
83. Buckley PF: The role of typical and atypical antipsychotic medications in the management of agitation and aggression. *Journal of Clinical Psychiatry* 1999; 60: 52-60.
84. Sajatovic M, Donenwirth K, Sultane D, Buckley PF: Admissions, length of stay, and medication use among women in an acute care state psychiatric facility. *Psychiatric Services* 2000; 51: 1278- 1281.
85. Sajatovic M, Madhusoodanan S, Buckley P: Schizophrenia in the elderly: guidelines for its recognition and treatment. *CNS Drugs* 2000; 13(2): 103-115.
86. Buckley PF, Buchanan RW, Tamminga CA, Schulz SC: Schizophrenia research: a progress report. *Schizophrenia Bulletin* 2000; 26(2): 411-419.
87. Buckley P, Miller A, Olsen J, Garver D, Miller DD, Csernansky J: When symptoms persist: clozapine augmentation strategies. *Schizophrenia Bulletin* 2001; 27: 613-624.
88. Buckley PF, Hasan S, Friedman L, Cerny C. Insight and schizophrenia. *Comprehensive Psychiatry* 2001;

- 42: 39-41.
89. Katz JG, Gintoli G, Buckley P: BART'S Place: bringing all relative's together: a special program for children and teenagers whose family members have serious mental illness. *Psychiatric Services* 2001; 52: 107.
 90. Buckley PF, Wiggins L, Sebastian S, Singer B. Treatment refractory schizophrenia. *Current Psychiatry Reports* 2001; 3: 393-400.
 91. Buckley PF, Dayem M, Weisser L, Parker G. Schizophrenia today: What do we know and how sure are we? *Journal of Psychiatric Practice* 2001; 7:244-246.
 92. Buckley PF, Miller DD, Singer B, Donenwirth K: The evolving clinical profile of atypical antipsychotic medications. *Canadian Journal of Psychiatry* 2001; 46: 285.
 93. Buckley PF, Krowinski AC, Miller D, Friedman L, Eaton E, Tronetti M, Lys C: Clinical and biochemical correlates of 'high-dose' clozapine therapy for treatment refractory schizophrenia. *Schizophrenia Research* 2001; 49: 225-227.
 94. Buckley PF, Friedman L, Jesberger JA, Schulz SC, Jaskiw G: Head size and schizophrenia. *Schizophrenia Research* 2002; 55: 99-104.
 95. Buckley PF. Broader therapeutic profile of atypical antipsychotics. *Biological Psychiatry* 2001; 50: 912-924.
 96. Emsley R, Buckley PF, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. *Journal of Psychopharmacology* 2003; 17(2): 205-210.
 97. Sajatovic M, Sultana D, Buckley P, Sivec H. Insight into illness and attitudes towards medication inpatients with schizophrenia. *Psychiatric Services* 2002; 53:1319-1321.
 98. Londino D, Wiggins L, Buckley PF. New uses for atypicals in pediatric patients. *Current Psychiatry* 2002; 1(10):45-52.
 99. Londino D, Wiggins L, Buckley PF. Using atypicals for patients without psychosis. *Current Psychiatry* 2002; 1(10):54-64.
 100. Sajatovic M, Sultana D, Bingham CR, Buckley PF, Donenwirth K. Gender related differences in clinical characteristics and hospital based resource utilization among older adults with schizophrenia. *International Journal of Geriatric Psychiatry* 2002; 17:542-548.
 101. Buckley PF, Goldstein J, Emsley R. Efficacy and tolerability of quetiapine in patients with chronic poorly responsive schizophrenia. *Schizophrenia Research* 2004; 66: 143-150.
 102. Momen M, Sebastian S, Buckley PF. Paradoxical reaction to fluoxetine. *Psychosomatics* 2003; 44:259-260.
 103. Buckley PF, Sinha D, Sebastian S, Stirewalt E. Aripiprazole - what the researchers think. *Current Psychiatry* 2003; 2:71-73.
 104. Kinon B, Ahl J, Stauffer, G, Hill A, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. *CNS Drugs* 2004; 18(9); 597-616.
 105. Buckley PF, Dean D, Bookstein F, Han F, Yankemovich Y, Singer B. A three dimensional morphometric study of craniofacial shape in schizophrenia. *American Journal of Psychiatry* 2005; 162:606-608.
 106. Buckley PF. Maintenance treatment for schizophrenia with quetiapine. *Human Psychopharmacology*

- 2004; 19:121-124.
107. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles J, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller D, McEvoy J, Rush AJ, Saeed SA, Schooler NR, Shon S, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project: Antipsychotic Algorithm for Schizophrenia Algorithm 2003 Update. *Journal of Clinical Psychiatry* 2004;65:500-508.
 108. Evans DR, Parikh VV, Khan, MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 2003 69(6):69:393-399.
 109. Sebastian CS, Glazer W, Buckley PF. Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia *Curr Med Chem*. 2004 Feb;11(3):329-42.
 110. Buckley PF, Hrouda DR, Friedman L, Noffsinger SG, Resnick PJ, Shingler KC. Insight and its relationship to violent behavior in patients with schizophrenia. *American Journal of Psychiatry* 2004; 161:1712-1714.
 111. Buckley PF, Evans D. First episode schizophrenia: a window of opportunity for therapeutic intervention. *Journal of Postgraduate Medicine* 2006; 51:5-19.
 112. Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt SV. Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and clozapine. *American Journal of Medical Genetics Part B (Neuropsychiatric Genetics)* 2005; 133B(1): 97-100.
 113. Buckley PF, Gowans A, Sebastian S, Pathiraja A, Brimeyer A, Stirewalt E. The boundary of schizophrenia: overlap with bipolar disorder. *Current Psychiatry Reports* 2004;2:49-56.
 114. Buckley PF. Neuroimaging of Schizophrenia: structural abnormalities and pathophysiological implications. *Neuropsychiatric Disease and Treatment*, 2005; 1(3) 193-204.
 115. Gilmore CS, Clementz BA, Buckley PF. Stimulus sequence affects schizophrenia-normal differences in event processing during an auditory oddball task. *Cognitive Brain Research* 2005; 24(2):215-227.
 116. Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. *Current Medical Research and Opinion* 2004 20(9):1357-1363.
 117. Buckley PF. Effective dosing and dose equivalency of second generation antipsychotic medications. *CNS Spectrum* 2004; 9(9):24-31.
 118. Buckley PF. From Acute to Maintenance: Strategies in the Treatment of Bipolar Disorder. *Advanced Studies in Medicine* 2004; 4:970-973.
 119. Buckley PF, Wirshing DA, Pierre J, Bushan P, Resnick S, Wirshing WC. Lack of insight and treatment adherence in schizophrenia. *CNS Drugs* 2007; 21:129-141.
 120. Buckley PF, Shendarkar N. Treatment-refractory schizophrenia. *Current Opinion in Psychiatry*, 2005; 18:165-173.
 121. Buckley PF. Dosing equivalency of second generation antipsychotic medications. *Journal of Clinical Psychopharmacology* 2005; 25:501-502.
 122. Lipkovich I, Deberdt W, Csernansky J, Buckley P, Peuskens J, Liu-Seifert H, Van Brunt D, Kollack-Walker S. Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. *Psychiatry Research* 2007; 41 (3-4): 305-310.
 123. Gilmore CS, Clementz BA, Buckley PF. Rate of stimulation affects schizophrenia-normal differences on the N1 auditory-evoked potential. *NeuroReport* 2004; 15(18):2713-2717.

124. Narasimhan M, Buckley PF. Early interventions when symptoms suggest a psychotic prodrome: implications from research to clinical practice. *Current Psychiatry*, 2005; 4:32-46.
125. Buckley PF, Miller DD, Singer B, Arena J, Stirewalt E. Clinicians appreciation of the metabolic effects of antipsychotic medications. *Schizophrenia Research* 2005; 77:281-288.
126. Buckley PF. Olanzapine: a critical review of recent literature. *Expert Opinion in Pharmacotherapy* 2005; 6:2077-2089.
127. Smith D, Buckley PF. Clinical and forensic considerations on the treatment of delusional disorders. *Behavioral Sciences and the Law* 2006; 24:351-367.
128. Buckley PF, Paulson B, Brecher M. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine. *Journal of Affective Disorders* 2007; 100 (S1): 33-43.
129. Buckley PF, Sebastian S. Aripiprazole: an appraisal of the translation of complex receptor effects into clinical outcomes. *Therapy* 2005; 2(5):699-707.
130. Buckley PF. Reflections on leadership as chair of a department of psychiatry. *Academic Psychiatry* 2006; 30:309-314.
131. Buckley PF, Mahadik SP, Terry A, Pillai A. Neurotrophins and schizophrenia. *Schizophrenia Research* 2007; 94 (1-3): 1-11.
132. Buckley PF, Kenna C, Bahmiller D, Powell I, Shevitz S, Fricks L. Resident education and recovery: Observations and commentary. *Academic Psychiatry* 2007; 36; 6: 435-438.
133. Narasimhan M, Buckley PF. Predictors of treatment response in bipolar disorder. *Current Advances in Bipolar Disorders* 2006; 5:36-44.
134. Stahl SM, Buckley PF. Negative symptoms in schizophrenia: a problem that will not go away. *Acta Psychiatrica Scandinavica* 2007; 115:4-11.
135. Buckley PF. Which antipsychotic do I choose now? CATIE 2 offers insight on efficacy, tolerability. *Current Psychiatry* 2006; 5:27-43.
136. Buckley, PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. *Journal of Clinical Psychiatry* 2006; 67: 5-9.
137. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotrophic factor in first episode schizophrenia. *Schizophrenia Research* 2007; 91: 1-5.
138. Buckley PF, Stahl SM. Negative symptoms of schizophrenia: opportunity or therapeutic cul-de- sac? *Acta Scandinavica Psychiatrica* 2007; 115: 93-100.
139. Buckley PF, Fenley G, Mabe A, Peeples S. Recovery and schizophrenia. *Clinical Schizophrenia and Related Psychoses* 2007; 1: 96-100.
140. Buckley PF, Loebel A, Harvey PD. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. *Schizophrenia Research* 2007; 94 (1-3): 99-106
141. Weiden P, Buckley PF. Reducing the burden of side effects during long term antipsychotic therapy: the role of switching medications. *Journal of Clinical Psychiatry* 2007, 68 (5.16):14-23.
142. Buckley PF. Receptor-binding profiles of antipsychotics: Clinical strategies when switching between agents. *Journal of Clinical Psychiatry* 2007; 68 (5.16): 5-9.
143. Buckley, PF, Meinsler L. The history of the American Association of Chairs of Departments of

- Psychiatry. *Academic Psychiatry* 2007; 31(2): 97-98.
144. Kinon B, Volavka J, Adams D, Citrome L, Stauffer G, Lindenmayer JP, Meltzer HY, Edwards S, Buckley PF, Lieberman JA. Standard and higher dose of olanzapine in patients with schizophrenia: A randomized, double-blind, fixed-dose trial. *Journal of Clinical Psychopharmacology* 2008; 28 (8): 392-400.
 145. Lindenmayer JP, Liv-Sevfer W, Kulkarni PM, Kinon B, Stauffer G, Edwards S, Chen L, Adams DH, Buckley PF, Citrome L, Volavka J. Medication nonadherence and treatment outcome in acutely in patients with schizophrenia of schizoaffective disorders with suboptimal prior response. *Journal of Clinical Psychiatry* 2009; 70 (7): 990-996.
 146. Foster A, Wang, Z, Usman M, Stirewalt E, Buckley FP. Pharmacogenetics and antipsychotic adverse effects: case studies and literature review. *Neuropsychiatric disease and treatment* 2008 (6).
 147. Moore, TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, Essock SM, Finnerty M, Marder SR, Miller DD, McEvoy JP, Robinson DG, Schooler NR, Shon SP, Stroup TS, Miller AL. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia 2006 Update. *Journal of Clinical Psychiatry* 2007; 68 (11): 175-1762.
 148. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA, Comparison of Atypicals in First Episode Study Group (inclusive of Buckley PF). Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. *Journal of Clinical Psychiatry*. 2008;69(1);106-113.
 149. Buckley PF. Factors that influence treatment success in schizophrenia. *Journal of Clinical Psychiatry*. 2008;69(S.3):4-10.
 150. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. *Journal of Clinical Psychiatry*. 2008;69(S.1):4-17.
 151. Chen Y, Guo JJ, Steinbuch M, Buckley PF, Patel NC. Risk of neuroleptic malignant syndrome in patients with bipolar disorder: a retrospective, population-based, case-control study. *International Journal of Psychiatry in Medicine*. 2009;39:439-443.
 152. Buckley PF, Miller B, Lehrer D, Castle D. Psychiatric comorbidities and schizophrenia. *Schizophrenia Bulletin*. 2009;35(2):383-402
 153. Talbott J, Faulkner L, Buckley PF. State-University Collaborations: A 25 year follow up. *Academic Psychiatry*. 2010; 34(2):125-127
 154. Gibson A, Patel NC, Lauriello J, Buckley PF. Antipsychotic combinations. Blind step or logical? *Current Psychiatry*. 2008;7:41-52
 155. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley PF, Eudicone J, McQuade R, Tran RV, Pikalov A, Assuncao, Talbott S: Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar 1 disorder: A post hoc analysis of pooled data from short-term and long-term aripiprazole trials. *Journal of Psychopharmacology*. 2010;24(7):1019-1029.
 156. Patel JK, Buckley PF, Hamer RM, Woolson S, McEvoy JP, Perkins D, Lieberman JA: Metabolic profiles of second generation antipsychotics in early psychosis: findings from the CAFÉ study. *Schizophr Res*. 2009;111(1-3):9 -16.
 157. Buckley PF, Rayburn W. Caring and Feeding of chairs of academic departments of psychiatry. *American Journal of Psychiatry*. 2010;167(4):376-378.

158. Buckley PF. Leadership development and academic psychiatry: more than 'on the job' training. *Psychiatric Bulletin*. 2009;33:401-403.
159. Brunette M F, O'Keefe C, Deuson R, Buckley P, Green A I. Quetiapine in patients with schizophrenia and alcohol disorders. *Dual Diagnosis*. 2009;2(3):203-211.
160. Peebles S, Mabe A, Fenley G, Buckley P F, Immersing psychiatric residents in the recovery model: An educational program evaluation. *Community Mental Health Journal*. 2009;45(4):239-245.
161. Covell N, Miller A, Nierenberg A, Myers B, Drake B, Findling R, Stein B, Jeste D, Goff D, Emslie G, Frazier J, Rush J, Calabrese J, Buckley P F, Deegan P, Kane J, Buchanan R, Roose S, Stroup S, Essock S. Identifying clinically questionable prescribing practices. *Psychiatric Services*. 2009;60(12):1595-1602.
162. Kane JM, David D, Potkin S, Buckley PF. A double-blind, randomized study comparing the efficacy and safety of sertindole and risperidone in patients with treatment-resistant schizophrenia. *Journal of Clinical Psychiatry* 2011; 72(7):194-204.
163. Keith SM, Buckley PF. Leadership experiences and Characteristics of Chairs of academic departments of psychiatry. *Academic Psychiatry* 2011;35(2):118-121.
164. Lipkovich IA, Deberdt W, Csemansky JG, Buckley PF, Peuskens, Kollack-Walkers, Rotelli M, Houston JP. Defining "good" and "bad" outcomes in patients with schizophrenia or schizoaffective disorders: a multidimensional data-driven approach. *Psychiatry Research* 2009; 170(2-3): 161-167.
165. Buckley PF, Grigsby KM. A propitious moment in the midst of crisis: A case study of organizational change in an academic department. *Academic Psychiatry*, 2011; 35(2): 143-148.
166. Buckley PF, Dauphinais D, Miller DD, Young G, Rawson J, Curd N. Academic Leadership Searches: Evolving Best Practices. *Journal of Healthcare Leadership* 2010; 2: 61-67.
167. Howell K, Pillai A, Buckley, PF. Brain derived neurotrophic factor: Findings in schizophrenia. *Current Opinion in Psychiatry* 2011; 24: 122-127.
168. Van Sant S, Buckley PF. Pharmacotherapy for treatment, refractory schizophrenia. *Expert Opinion on Pharmacotherapy* 2011; 12(3): 411-434.
169. Miller B, Buckley, P, Seabolt, SN, Kirkpatrick B, Mellor A. Metaanalysis of cytokines alterations in schizophrenia: Clinical status and antipsychotic effects. *Biological Psychiatry* 2011; 20 (7); 663- 671.
170. Oglum K, Messias E, Buckley, PF. New-age patient communications through social networks. *Hospital and General Psychiatry* 2011; 33(2): 200.
171. Keefe RST, Vinogradov S, Medalia A, Buckley PF, Caroff SN, D'Souza DC, Harvey PD, Graham KA, Hamer RM, Marder SM, Miller DD, Olson SJ, Patel JK, Velligan D, Walker TM, Haim AJ, Stroup ST. Feasibility and pilot efficacy results from one multi-site cognitive remediation in the schizophrenia trials network (CRSTN) study. *Journal of Clinical Psychiatry* 2012; 73(7): 1016-22.
172. Kaddurah-Dauk, R, McEvoy J, Baillie R, Zhu H, Yao J, Nimgaonkar VL, Buckley, PF, Keshavan MS, Georgiades A, Nasrallah H: Impaired Plasmalogens in Patients with Schizophrenia: *Psychiatry Research* 2012; 198(3): 347-352.
173. Ahmed, A. O., Buckley, P. F., & Mabe, P. A. Latent structure of psychotic experiences in the general population. *Acta Psychiatrica Scandinavica* (2012): 125, 54-65.
174. Buckley PF, Rayburn WF: Turnover of first-time chairs in departments of psychiatry. *Academic Psychiatry* 2011; 35(2): 126-128.

175. Compton MT, Chan RCK, Walker, EF, Buckley, PF: Minor physical anomalies: potentially informative vestiges of fetal developmental disruptions in schizophrenia. *International Journal of Developmental Neuroscience* 2011; 29: 245-250.
176. Buckley PF, Citrome L, Vittaco M, Nichita K: Psychopharmacology of Aggression in Schizophrenia. *Schizophrenia Bulletin* 2011; 37(5): 930-936.
177. Buckley PF. Bromization: The Truths we know About the Psychopharmacology of Schizophrenia. *Journal of Nervous and Mental Diseases*. 2011; 199(10):736-737.
178. Stroup TS, McEvoy JP, King KD, Hamer RH, LaVange LM, Swartz MS, Rosenbeck RA, Perkins DO, Nussbaum AM, Lieberman JA. Schizophrenia Trials Network (inclusive of Buckley PF). A randomized trial comparing the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of antipsychotics for metabolic problems (CAMP). *American Journal of Psychiatry*. 2011; 168:947-956.
179. Ahmed, AO, Green, BA, Buckley, PF, & McFarland, ME. Taxometric analyses of paranoid and schizoid personality disorders. *Psychiatry Research*. 2012; 196(1): 123-132.
180. Ahmed AO, Green BA, Goodrum NM, Doane NJ, Birgenheir D, Buckley PF. Does a latent class underlie schizotypal personality disorder? Implications for the schizophrenia. *Journal of Abnormal Psychology*. 2013; 122(2):475-491.
181. Ahmed AO, Birgenheir D, Buckley PF, Mabe PA. A Psychometric study of recovery among certified peer specialists. *Psychiatry Research*. 2013; 209(3):721-731.
182. Mallon, WT, Buckley, P. The Current State and Future Possibilities of Recruiting Leaders in Academic Health Centers. *Academic Medicine*. 2012; 87(7): 1171-6.
183. McEvoy J, Baillie RA, Zhu H, Buckley PF, Keshavan MS, Nasrallah HA, Yao J, Kaddurah-Daouk R. Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics. *PLoS One*. 2013; 8(7): e68717.
184. Goff D, McEvoy J, Citrome L, Mech A, Bustillo J, Gil, R, Buckley P, Manschreck T, Achytes E, Macklin E. High-Dose Oral Ziprasidone versus Conventional Dosing in Schizophrenia Patients with Residual Symptoms: The ZEBRAS Study. *Journal of Clinical Psychopharmacology*. 2013; 33(4):485-490.
185. Miller BJ, Culppepper N, Buckley PF, Rapaport MH. Prenatal inflammation and Neurodevelopment in Schizophrenia: A Review of Human Studies. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2013; 42:92-100.
186. Pillai A, Buckley PF, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J, Ginsberg SD, Pomara N, Mehta PD, Zetterberg H, Blennow K. Plasma BDNF Levels Vary in Relation to Body Weight in Females. *PLoS One*. 2012; 7(7): e39358.
187. Green AI, Brunette MF, Dawson R, Buckley PF, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy D, O'Keefe C, Sommi R, Steinbook RM, Weeks, M. Long-Acting Injectable vs. Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Disorder: A Randomized Trial. *Journal of Clinical Psychiatry*. 2015; 76(10):1359-1365.
188. Miller BJ, Graham KL, Bodenheimer CM, Culppepper NH, Waller JL, Buckley PF. A Prevalence Study of Urinary Tract Infections in Acute Relapse of Schizophrenia...More than a Chance Observation? *Journal of Clinical Psychiatry*. 2013; 74(3):271-277.
189. Miller BJ, Mellor A, Buckley PF. Total and Differential White Blood Cell Counts, High-Sensitivity C-Reactive Protein, and the Metabolic Syndrome in Non-Affective Psychoses. *Brain, Behavior, and*

- Immunity. 2013; 31:82-89.
190. Flatow J, Miller BJ, Buckley PF. Meta-Analysis of Oxidative Stress in Schizophrenia. *Biological Psychiatry*. 2013; 74:400-409.
 191. Pato MT, Sobell J, Medeiros H, Abbott C, Sklar B, Buckley PF, Bromet E, Escamilla M, Fanous A, Lehrer D, Macciardi F, Malaspina D, McCarroll S, Marder S, Motley C, Nicollini H, Perkins D, Purcell S, Rapaport M, Sklar P, Smoller J, Knowles JA, Pato CN. The Genomic Psychiatry Cohort: Partners in Discovery. *American Journal of Medical Genetics*. 2013; 162(4):306-312.
 192. Miller BJ, Bodenheimer CM, Culpepper NJ, Graham KL, Buckley PF. Differential White Blood Cell Counts May Predict Urinary Tract Infection in Acute Non-Affective Psychosis. *Schizophrenia Research*. 2013; 147(2-3):400-401.
 193. Ezeoke A, Mellor A, Buckley PF, Miller BJ. A systematic quantitative review of blood autoimmunity elevations in schizophrenia. *Schizophrenia Research*. 2013; 150(1):245-251.
 194. Miller B, Gassama B, Sebastian D, Buckley P, Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. *Biological Psychiatry*. 2013; 74(1):993- 999.
 195. Pandya C, Hoda M, Kutiyanawalla A, Buckley P, Pillai A. Differential effects upon brain and serum BDNF levels in rats as response to continuous and intermittent administration strategies of two second generation antipsychotics. *Schizophrenia Research*. 2013; 35(1):3-9.
 196. Ahmed AO, Serdarevic M, Mabe PA, Buckley PF. Triumphs and challenges of transforming a state psychiatric hospital in Georgia. *International Journal of Mental Health Promotion*. 2013; 15(2):68-75. The t
 197. Graham KL, Bodenheimer CM, Ezeoke A, Buckley PF, Miller BJ. Urinary Tract Infections in Acute Relapse of Psychosis. *Journal of Clinical Psychiatry*. 2014; 75(4):379-385.
 198. Hartz SM, Pato CN, Medeiros H, Cavazo-Rehg P, Sobell JL, Knowles JA, Bierut LJ, Pato MT; for the Genomic Psychiatry Cohort Consortium (inclusive of Buckley, PF). Comorbidity of Severe Psychotic Disorders with Measure of Substance Use. *JAMA Psychiatry*. 2014; 71(3):248-254.
 199. Monroe JM, Buckley PF, Miller BJ. Meta-Analysis of Anti-*Toxoplasma gondii* IgM Antibodies in Acute Psychosis. *Schizophrenia Bulletin*, 2015; 41(4):989-998.
 200. Foster A, Buckley PF. The use of simulation to teach suicide risk assessment to health professions trainees – rationale, methodology and a proof of concept demonstration with a virtual patient. *Academic Psychiatry*, 2015; 39(6):620-629.
 201. McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. *JAMA*, 2014; 311(19):1978-87.
 202. Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopeloweiz A, Lauriello J, Manschreck T, Mendeloweiz A, Miller DD, Severe JB, Wilson DR, Ames, D, Bustillo J, Mintz J, Kane JM. Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. *Schizophrenia Bulletin*, 2015; 41(2):449-459.
 203. Miller BJ, Stewart A, Schrimsher J, Peeples, D, PF Buckley. How Connected are People with Schizophrenia? Cell Phone, Computer, Email, and Social Media Use. *Psychiatry Research*, 2015; 225(3):458-463.
 204. Buckley PF, Miller BJ, Pillai A, Kirkpatrick B. Cysteamine, a Pro-BDNF drug, as an Adjunctive Treatment for Schizophrenia. *Schizophrenia Research*. 2014; 158(1-3):268-269.

205. Mabe PA, Ahmed AO, Duncan GL, Fenley, G, Buckley PF. Project GREAT: Immersing Physicians and Doctorally-Trained Psychologists in Recovery-Oriented Care. *Professional Psychology: Research and Practice*, 2014; 45:347-356.
206. Miller BJ, Kandhal P, Rapaport MH, Mellor A, Buckley P. Total and Differential White Blood Cell Counts, High-Sensitivity C-Reactive Protein, and Cardiovascular Risk in Non-Affective Psychoses. *Brain, Behavior, and Immunity*. 2015; 45:28-35.
207. Nuss MA, Robinson B, Buckley PF. A Statewide Strategy for Expanding Graduate Medical Education (GME) by Establishing New Teaching Hospitals and Residency Programs. *Academic Medicine* 2015; 90(9):1264-1268.
208. McEvoy J, Millet R, Dretchen K, Morris A, Corwin M, Buckley P. Quantitative Levels of Aripiprazole Parent Drug and Metabolites in Urine. *Psychopharmacology*. 2014; 231(23):4421- 4428.
209. Williams DR, Miller BJ, Tatugade A, Avasthi R, Buckley PF. Unresponsive and mute after he smoked 'Spice'. *Current Psychiatry*. 2016; 15(3):65-70.
210. Foster A, Chaudhary N, Kim T, Waller JL, Boris M, Wang J, Cordar A, Lok B, Buckley PF. Using Virtual Patients to Teach Empathy: A Randomized Controlled Study to Enhance Medical Students' Empathic Communication. *Simulation Healthcare*. 2016; 11(3):181-9.
211. Duan J, Shi J, Florentino A, Leites C, Chen X, Moy W, Chen J, Alexandrov B, Usheva A, He D, Freda J, O'Brien NL, Molecular Genetics of Schizophrenia Collaboration, Genomic Psychiatry Cohort Consortium (inclusive of Buckley PF), McQuillin A, Sanders AR, Gershon EL, DeLisi LE, Bishop A, Gurling HMD, Pato MT, Levinson DF, Kendler KS, Pato CN, Gejman PV. A rare functional noncoding variant at the GWAS-implicated *MIR137/MIR2682* locus may confer risk to schizophrenia and bipolar disorder. *American Journal of Medical Genetics, Neuropsychiatric Genetics* 2014; 95(6):744-753.
212. Lehrer D, Nahas R, Malaspina D, Miller B, Buckley P, Pato M, Pato C, the Genomic Psychiatry Cohort. Paternal age effect: Replication in schizophrenia with intriguing dissociation between bipolar patients with and without psychosis. *Am J Med Genet B Neuropsychiatr Genet*. 2016; 171(4):495-505.
213. Malaspina D, Walsh-Messinger J, Antonius D, Draxler R, Rothman K, Puthota J, Gilman C, Feuerstein JL, Keefe D, Goetz D, Goetz RR, Buckley P, Lerner, D, Pato C, Pato M. Parental age effects on odor sensitivity in healthy subjects and schizophrenia patients. *Am J Med Genet B Neuropsychiatr Genet*. 2016; 171(4):513-20.
214. Cieslak, K, Pato M, Buckley P, Pato C, Sobell J, Medeiros H, Zhao Y, Ahn H, Genomic Psychiatry Cohort, Malaspina D. Traumatic brain injury and bipolar psychosis in the Genomic Psychiatry Cohort. *Am J Med Genet B Neuropsychiatr Genet*. 2016; 171(4):506-12.
215. Estrada E, Hartz SM, Tran J, Hilty D, Sklar P, Smoller J, Genomic Psychiatry Cohort Consortium, (inclusive of Buckley P), Pato MT, Pato CN. Nicotine dependence and psychosis in Bipolar disorder and Schizoaffective disorder, Bipolar type. *Am J Med Genet B Neuropsychiatr Genet*. 2016; 171(4):521-4.
216. Ahmed AO, Hunter KM, Mabe AP, Tucker S, Buckley PF. The Professional Experiences of Peer Specialists in the Georgia Mental Health Consumer Network. *Community Mental Health Journal*. 2015; (9):854-858.
217. Hamm JP, Bobilev AE, Hayrynen LK, Hudgens-Haney ME, Oliver WT, Parker DA, McDowell JE, Buckley PF; Clementz BA. Stimulus train duration but not attention moderates γ -band entrainment abnormalities in schizophrenia. *Schizophr Res* 2015;165:97-102.
218. Miller BJ, Dias J, Lemos H, Philip N, Buckley P. An Open-Label, Pilot Trial of Adjunctive Tocilizumab in Schizophrenia. *J Clin Psychiatry* 2016; 77(2):275-276.

219. Ahmed AO, Hunter KM, Goodrum NM, Batten N-J, Birgenheir D, Hardison E, Dixon T, Buckley PF. A Randomized Study of Cognitive Remediation for Forensic and Mental Health Patients with Schizophrenia. *Journal of Psychiatric Research* 2015; 68:8-18.
220. Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. *Psychiatric Research* 2015; 226(1):1-13.
221. Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller DD, Wilson DR, Ames D, Bustillo J, Kane JM, Looney S. Low Rates of Relapse in a Pragmatic, 30-month Schizophrenia Relapse Prevention Study. *Psychiatric Services*. 2016;67(12):1370-1372.
222. Miller BJ, Goldsmith DR, Paletta N, Wong J, Kandhal P, Black C, Rapaport MH, Buckley PF. Parental type 2 diabetes in patients with non-affective psychosis. *Schizophrenia Research* 2016; 175(1- 3):223-5.
223. Miller BJ, Wang A, Wong J, Paletta N, Buckley PF. Electronic Cigarette Use in Patients with Schizophrenia: Prevalence and Attitudes. *Annals of Clinical Psychiatry*. 2017; 29(1):4-10.
224. Miller BJ, Buckley PF. Monoclonal Antibody Immunotherapy in Psychiatric Disorders. *The Lancet Psychiatry*. 2017; 4(1):13-15.
225. Moyer KH, McEvoy JP, Mabe A, Buchanan E, Venkatesan A, Buckley PF. Prioritizing Harm. *Journal of Personality Assessment*. 2017;99:1,78-82
226. Miller BJ, Buckley, PF, McEvoy JP. Inflammation, Substance Use, Psychopathology, and Cognition in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study. *Schizophrenia Research*. 2018; 195:275-282.
227. Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF. Predicting relapse in schizophrenia: Is BDNF a plausible biology marker? *Schizophrenia Research*. 2018; 193:263-268.
228. Riley G, Perrin M, Vaez-Azizi LM, Ruby E, Goetz RR, Dracxler R, Messinger JW, Keefe DL, Buckley PF, Szeszko P, Malaspina D. Telomere Length and Early Trauma in Schizophrenia. *Schizophrenia Research*. 2018; 199:426-430.
229. Gershon ES, Pearlson G, Keshavan MS, Tamminga C, Clementz B, Buckley PF, Alliey-Rodriguez N, Liu C, Sweeney JA, Keedy, S, Meda SA, Tandon N, Shafee R, Bishop JR, Ivleva EI. Genetic Analysis of Deep Phenotyping Studies in Common Disorders. *Schizophrenia Research*. 2018; 195:51-57.
230. Kelly, D.L., Powell, M. M., Wehring, H., Sayer, M.A., Kearns, A.M., Hackman, A.L, Buchanan, R.W., Nichols, R.B., George, N.A., Adams, H.A., Richardson, C.M., Vyas, G., McMahon, Earl, A.K., Sullivan, K. M., Fang, L., Luttrell, S., Dickerson, F.B., Feldman, S.M., Shim, J.C., Narang, S., Koola, M.M., Buckley, P., RachBeisel, J.A., McEvoy, J. P. Adjunctive aripiprazole treatment for premenopausal women with schizophrenia: Results from the DAAMSEL clinical trial. *Journal of Clinical Psychopharmacology*. 2018; 38(4): 317-326.
231. Miller BJ, Parker CB, Rapaport MH, Buckley PF, McCall WV. Insomnia and suicidal ideation in nonaffective psychosis. *Sleep*. 2019; 42(2):215.
232. Alliey-Rodriguez N, Grey TA, Shafee R, Padmanabhan J, Tandon N, Liu S, Zhou X, Linger M, Spring J, Coppes L, Reis K, Rubin D, Keshavan MS, Gage D, McCarroll S, Bishop JR, Hill S, Reilly JL, Lencer R, Clementz BA, Buckley PF, Meda S, Narayanan B, Pearlson G, Ivleva EI, Tamminga C, Sweeney JA, Curtis D, Badner JA, Keedy S, Rapoport J, Sullivan P, Glahn DC, Liu C, Gershon ES. Deep Phenotyping Genome- Wide Association Study Identifies Genetic and Neurodevelopmental Biomarkers Associated

- with Brain Ventricular Enlargement in Psychosis. *Translational Psychiatry*. 2019; 9(1):20.
233. Weickert T, Weickert CS, Lee CH, Lenroot R, Bruggeman J, Galletly C, Liu D, Balzan R, Pillai A, Buckley PF. Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia. *Schizophrenia Research*. 2019; 202:212-217.
234. Goldsmith DR, Haroon E, Miller AH, Strauss GP, Buckley PF, Miller BJ. TNF and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. *Schizophrenia Research*. 2018; 199: 281-284.
235. Bigdeli TB, Genovese G, Georgakopoulos P, Iyegbe C, Myers J, Peterson RE, Stahl EA, Volderrama J, Alott C, Achtyes ED, Azevedo M, Bellieseau RA, Bevilacqua B, Braff DL, Bromet EJ, Buckley PF, Pato CN. Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. *Molecular Psychiatry*. 2019; 86(2):110-119.
236. Charney AW, Stahl EA, Green EK, Chen CY, Moran JL, Chambert K, Belliveau Jr RA, Forty Liz, Gordon-Smith K, Lee PH, Bromett EJ, Buckley PF, et al. Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. *Biological Psychiatry*. 2019; 86(2):110-119.
237. Steele M, Pennell S, Prescott JE, Steineke A, Sweeney N, Buckley PF. Leadership Development for Future Medical School Deans: Outcomes of the AAMC Council of Deans Fellowship Program. *Academic Medicine*. 2020; 95 (12):1887-1892.
238. Mahncke HW, Kim SJ, Rose A, Stasio C, Buckley P, Caroff S, Duncan E, Yasmin S, Jarskog LF, Lamberti JS, Nuechterlein K, Strassnig M, Velligan D, Ventura J, Walker T, Stroup TS, Keefe RSE: Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. *Schizophrenia Res*. 2019; 208:182-189.
239. Alliey-Rodriguez N, Grey T, Shafee R, Asif H, Lutz O, Bolo N, Padmanabhan J, Tandon N, Klinger M, Reis K, Spring J, Coppes L, Zeng V, Hegde R, Hoang D, Bannai D, Nawaz U, Henson P, Liu S, Gage D, McCarroll S, Bishop J, Hill S, Reilly J, Lencer R, Clementz B, Buckley PF, Glahn D, Meda S, Narayanan B, Pearlson G, Keshavan M, Ivleva E, Tamminga C, Sweeney J, Curtis D, Badner J, Keedy S, Rapoport J, Liu C, Gershon E. NRXN1 is associated with enlargement of the temporal horns of the lateral ventricles in psychosis. *Translational Psychiatry*. 2019; 9 (1):230.
240. Asif H, Alliey-Rodriguez N, Keedy S, Tamminga CA, Sweeney JA, Pearlson G, Clementz BA, Keshavan MS, Buckley PF, Liu C, Neale B, Gershon ES. GWAS significance thresholds for deep phenotyping studies can depend upon minor allele frequencies and sample size. *Molecular Psychiatry*. 2021. Doi: 10.1038/S4138-020-0670-3.
241. Ahmed A, Kramer S, Sarig N, Flynn J, Hansen M, Martin V, Pillai A, Buckley PF. A Meta-analysis of Brain-Derived Neurotrophic Factor (BDNF) Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels. *Neuropsychobiology*. 2021. Doi: 10.1159/00514126.
242. Gotra MY, Hill SK, Gershon ES, Tamminga CA, Pearlson GD, Keshavan MS, Clementz BA, Buckley PF, Sweeney JA, Keedy SK. Distinguishing Patterns of Impairment on Inhibitory Control and General Cognitive Ability Among Bipolar with or without Psychosis, Schizophrenia, and Schizoaffective Disorder. *Schizophrenia Research*. 2020; 223:148-157.
243. Dow AW, Dipiro JT, Gidden J, Buckley PF, Santen SA. Emerging from the COVID Crisis with a Stronger Healthcare Workforce. *Academic Medicine*. 2020; 25 (12):1823-1826.
244. Bigdeli TB, Fanous AH, Li Y, Rajeevan N, Sayward F, Genovese G, Gupta R, Radhakrishnan, Malhotra AC, Sun N, Lu Q, Hu Y, Li B, Chen Q, Mane S, Miller P, Cheung KH, Lur RE, Greenwood TA, Braff DL, Consortium on Genetics of Schizophrenia, Achtyes ED, Buckley PF, Lehrer D... and Harvey PD.

- Genome-wide association studies of schizophrenia and bipolar disorder in a diverse cohort of United States veterans. *Schizophrenia Bulletin*. 2021. (in press).
245. Buckley PF. Treatment – refractory schizophrenia. *Focus*. 2020; 18(4):364-367.
 246. Hewlett H, Buckley P, Woleben C, Feldman M, Alford J, Santen S. Impact of scribe experience on undergraduate medical education. *Medical Science Educator*. 2020; 30:1721
 247. O'Donovan M, Psychiatric Genetics Consortium (inclusive of P Buckley). Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. *Nature Medicine* (in press).
 248. Keepers GA, Fochtmann L, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia. *The American Journal of Psychiatry*. 2020; 177 (9): 868-872.
 249. Ahmed AO, Kramer S, Sarig N, Flynn J, Hansen R, Root JC, Pillai A, Buckley PF. A meta-analysis of brain-derived neurotrophic factor (BDNF) effects on a brain volume in schizophrenia: genotype and serum levels. *Neuropsychobiology*. 2021. (in press)
 250. Landi I, Kaji D, Cotter L, Van Vleck T, Belbin G, Preuss M, Loos R, Kenny E, Glicksberg BS, Beckmann N, O'Reilly P, Schadt E, Achtyes ED, Buckley PF, Lehrer D, Malaspina D, McCarroll SA, Rapaport MH, Fanous AH, Pato MT, Pato CN, Genomic Psychiatry Cohort (GPC) Investigators, Bigdeli T, Nadkarni GN, Charney AW. Polygenic risk scores lack prognostic value in adults with severe mental illness. *Nature Medicine* (in press).
 251. Nallani, MC, Powell MM, Pugh S, Kearns AM, Adams HA, Weiner E, Wehring HJ, McEvoy JP, Buckley PF, Liu F, Buchanan RW, Kelly DL. Physical and sexual health of women diagnosed with schizophrenia. *Journal of Psychiatric Research*. 2021 (submitted for publication).
 252. de Leon, J, Schoretsanitis G, Smith RL et al (inclusive of Buckley PF). An international adult guideline for making clozapine titration safer worldwide by using 6 ancestry-based personalized dosing titrations, c-reactive protein and, when possible, clozapine levels. *Pharmacopsychiatry* (in press).
 253. Duvivier RJ, Buckley PF, Martin A, Boulet J. International medical graduates in the United States psychiatry workforce. *Academic Psychiatry* (submitted for publication).

Other, Non-Peer Reviewed Manuscripts

1. Buckley PF, Svendsen D, Herndon S, Hogan M: Managed care in public mental health systems: the Ohio initiative. *Journal of Practical Psychiatry and Behavioral Health* 1999; 5: 44-46.
2. Buckley PF, Miller A, Chiles JA, Sajatovic M: Implementing effectiveness research and improving care for schizophrenia in real-world settings. *American Journal of Managed Care* 1999; 5:47-56.
3. Buckley PF: Comprehensive disease management for schizophrenia. *Drugs of Today* 2000; 36(5): 267-280.
4. Buckley PF. Ziprasidone: pharmacology, clinical progress and therapeutic promise. *Drugs for Today* 2000; 36: 583-589.
5. Buckley PF, Sinha D. Violence and schizophrenia: emerging standards of care. *Psychiatric Times* 2002 Vol. XIX, 12:1-4.
6. Buckley PF, Wiggins LD. Schizophrenia Revealed: From Neurons to Social Interactions. Book Review.

- Journal of Nervous & Mental Disease 2002; 190(5):346.
7. Wirshing DA, Buckley PF. Schizophrenia: Treatment Challenges. *Psychiatric Times* 2003; XXI: 40- 41.
 8. Buckley PF, Mahadik S, Evans D, Stirewalt E. Schizophrenia: causes, course and neurodevelopment. *Current Psychiatry Reports* 2003; 1:41-49.
 9. Buckley PF. Aripiprazole: Efficacy and tolerability profile of a novel-acting atypical antipsychotic. *Drugs of Today* 2003; 39(2):145-151.
 10. Buckley PF. Timely help for the suicidal patient. *Psychiatric Issues in Emergency Care Settings*. 2004; 3:6-7.
 11. Buckley PF. Second generation antipsychotic medications in the treatment of mood disorders: focus on Aripiprazole. *Drugs of Today* 2005; 41:5-11.
 12. Buckley PF. The bipolar spectrum: critical diagnosis. *Clinical Psychiatry News* 2005;53-55.
 13. Ginsberg DL, Schooler NR, Buckley PF, Harvey PD, Weiden PJ. Optimizing treatment for schizophrenia: enhancing affective/cognitive and depressive functioning. *CNS Spectrum* 2005; 10(2):1-15.
 14. Weiden PJ, Young AH, Buckley PF. The art and science of switching antipsychotic medications, part 1. *J Clin Psychiatry*, 2006; 67(11):e15.
 15. Buckley PF, Brown ES. Prevalence and consequences of dual diagnosis. *J Clin psychiatry*, 2006; 67(7): e01.
 16. Buckley PF. Introduction: the art and science of switching antipsychotic medications. *J Clin Psychiatry*. 2007; 68 Suppl 6:4.
 17. Nichita EC, Buckley PF. Informed consent and competency: doctor's dilemma on the consultation liaison service. *Psychiatry (Edgmont)*. 2007 Mar; 4(3): 53-5.
 18. Weiden PJ, Miller AL, Lambert TJ, Buckley PF. The art and science of switching antipsychotic medications, part 2. *J Clin Psychiatry*. 2007; 68(1): e02.
 19. Foster A, Uzman M, Buckley PF. Schizophrenia: neurobiology. *Current Psychiatry Reports* 2007;9(40); 337-347.
 20. Lieberman JA, Buckley PF, Perkins JA. Neuroprotection: a new strategy in the treatment of schizophrenia. *CNS Spectrum* 2007; 12(518):1-16.
 21. Buckley, PF, Correll C, Miller AL. First episode schizophrenia: a window of opportunity for best practices. *CNS Spectrum* 2007; 12 (5; 9): 1-12.
 22. Buckley, PF. Update on the treatment and management of schizophrenia and bipolar disorder. *CNS Spectrum* 2008; 13 (2; S1): 1-10.
 23. Buckley PF, Foster A, Miller B. Schizophrenia: Host Vulnerability and risk of metabolic disturbances during treatment with antipsychotics. *Focus* 2008; 7 (2); 172-179.
 24. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2008; 2(1):29-32.
 25. Cascade EF, Kalali AH, Buckley PF. Current management of schizophrenia: Antipsychotic monotherapy versus combination therapy. *Psychiatry* 2008; 5(5): 28-30.
 26. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2008; 2(3):199-201.
 27. Buckley PF, Foster A. Schizophrenia: Current concepts and approaches to patient care. *American Drug and Health Benefits* 2008; 1 (4): 13-22.

28. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2008; 2(2):117-122.
29. Buckley PF: *Journal of Clinical Psychiatry: The Medical Basis of Psychiatry - Third Edition*. Book Review. Physicians Postgraduate Press, Inc., Totowa, New Jersey, 2008.
30. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2009; 3(2):77-79.
31. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2009; 3(1):15-17.
32. Cascade E, Kalali A, Buckley PF. Treatment of schizoaffective disorder. *Psychiatry* 2009; 6 (3): 15- 17.
33. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2009; 2(4):280-281.
34. Lenderts S, Kalali A, Buckley PF. Generic penetration in the retail atypical antipsychotic market. *Psychiatry* 2010; 7 (3): 17-18.
35. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2010; 4(2):103-104.
36. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2010; 4(1):27-28.
37. Buckley, PF. Getting a job: Wowing them at the interview. *Psychiatric Times* 2010; XXVII (9): 8/20.
38. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2010; 4(3):158-260.
39. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2011; 5(3):121-123.
40. Azziz R, Buckley PF. Georgia Health Sciences University: New name, school still addressing physician shortages in Georgia. *Journal of the Medical Association of Georgia*. 2011; 100(1):21.
41. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2011; 5(2):69-71.
42. Buckley PF: *Schizophrenia: Current Science and Clinical Practice*. Book Review. Wiley-Blackwell, New York, New York, 2011.
43. Buckley PF. GHSU: Addressing the state's physician shortage. *Journal of the Medical Association of Georgia*. 2011; 100(3): 21-22.
44. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2011; 5(1):12-14.
45. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2011; 4(4):215-216.
46. Van Sant S, Ahmed AO, Buckley PF. Schizophrenia, sexuality, and recovery. *Journal of Ethics and Mental Health*. 2012;7(1):1-5.
47. Buckley PF: *Journal of Clinical Psychiatry: The Age of Insight: The Quest to Understand the Unconscious in Art, Mind, and Brain, from Vienna 1900 to the Present*. Book Review. *American Journal of Psychiatry*, July 2012; 169(7): 764-765.
48. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2012; 6(3):105-106.
49. Buckley PF. Evidence suggests complex links between violence and schizophrenia. Interview by Bridget M. Kuehn. *JAMA*. 2012; 308(7): 658-9.
50. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2012; 6(2):53-54.
51. Buckley PF. Experiencing Psychosis: Personal and Professional Perspectives. *Journal of Nervous & Mental Disease* 2012; 200(10): 915-917.
52. Ahmed AO, Buckley, PF, & Mabe, PA. International efforts at implementing and advancing the recovery model. *International Psychiatry* 2012; 9(1), 4-6
53. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2012; 6(1):12-13.

54. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2012; 5(4):183-184.
55. Miller BJ, Buckley P. Is relapse in schizophrenia an immune-mediated effect? *FOCUS: The Journal of Lifelong Learning in Psychiatry* 2012; 10(2): 115-123.
56. Ahmed AO, Buckley PF, Hanna M. Neuroimaging Schizophrenia: A Picture is Worth a Thousand Words, but is it saying anything important? *Current Psychiatry Reports*, 2013;15(3):345.
57. Ahmed AO, Mabe PA, Buckley PF. Peer specialists as educators for recovery-based systems transformation. *Psychiatric Times*. 2012; 29:1-7.
58. Buckley PF, Curd N. Administrative Skills in Psychiatry: Leadership and Career Development. *Journal of Psychiatric Administration and Management*. 2013; 1(2):69-72.
59. Van Sant S, Buckley PF. Violence and Schizophrenia. *Journal of the Medical Association of Georgia*. 2013; 102(1): 16-17.
60. Buckley PF. Clinical News. *Clinical Schizophrenia & Related Psychoses*. 2013; 6(4):168-169.
61. Ahmed AO, Buckley PF. *The Archaeology of Mind*. (2012). W.W. Norton & Company, Inc. Book Review. *Journal of Nervous and Mental Disease*. 2013; 201(8): 719-720.
62. Buckley PF. Clinical News: New Treatments Under Development, Stigma, Genetics and Nosology, Genetic Counseling Coming of Age. *Clinical Schizophrenia & Related Psychoses*. 2013; 7(1): 13-15.
63. Vitacco MJ, Buckley PF. Substance abuse comorbidity in schizophrenia: Conceptual and clinical issues. *Psychiatric Annals*. 2013; 43(10):454-457.
64. Buckley PF. Clinical News: New drugs update, *DSM-5*, brain initiative, urinary tract infections, prodromal research, stigma and global outreach. *Clinical Schizophrenia and Related Psychoses*. 2013; 7(2): 1-3.
65. Weickert CS, Weickert TW, Pillai A, Buckley PF. Biomarkers in Schizophrenia: A Brief Conceptual Consideration. *Disease Markers*. 2013; 35(1): 3-9.
66. Hwang MY, Buckley PF. Comorbidity in schizophrenia: Clinical management and conceptual issues. *Psychiatric Annals*. 2013; 43(10):435-436.
67. Waddington JL, Buckley PF. Psychotic depression: An underappreciated window to explore the dimensionality and pathobiology of psychosis. *Schizophrenia Bulletin*. 2013; 39(4):754-55.
68. Buckley PF. The medical school Dean: Leadership and workforce development. *Academic Psychiatry*. 2014;38(1):82-85.
69. Buckley PF. Wayne Fenton Award for Exceptional Clinical Care. *Schizophrenia Bulletin*. 2013.
70. Buckley PF. Clinical News: Updates on new putative antipsychotics, antipsychotic effects in young children and adolescents with psychosis, novel pharmacologic approaches to negative symptoms and cognitive impairment in schizophrenia. *Clinical Schizophrenia and Related Psychoses*. 2013; 7(3):112-114.
71. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Müller N, Kanchanatawan B, Maes M. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013; 42:1-4.
72. Buckley PF. Clinical News: Prodrome conversion to psychosis over time, immunological and neuroimaging putative biomarkers, metabolic syndrome and appropriate 'best practices' with

- antipsychotic medications, compulsory treatment, mental health parity 'comes of age'. *Clinical Schizophrenia & Related Psychoses*. 2014; 7(4):195-197.
73. Buckley PF: Schizo-Obsessive Disorder. Book Review. Cambridge University Press, New York. *J Clin Psychiatry*. 2014; 75(5):e466.
 74. Buckley PF. Clinical News: National awards for **CS** Editorial Board Members, neuroinflammation, putative antipsychotics, dopamine imbalance, metabolic dysfunction, cognitive deficits at the core of schizophrenia, recovery. *Clinical Schizophrenia & Related Psychoses*. 2014; 8(1):5-7.
 75. Buckley PF. Clinical News: SIRS, antipsychotics for refractory schizophrenia, the trajectory of cognitive decline in schizophrenia, head injury and psychosis risk, marijuana and psychosis risk. *Clinical Schizophrenia & Related Psychoses*. 2014; 8(2):70-72.
 76. Buckley PF. Clinical News: Update on new putative antipsychotic medications, old and new long-acting injectable antipsychotics, genetics extended research, marijuana and psychosis, NIH Brain initiative, bereavement as a risk factor for schizophrenia, virtual reality and social skills in schizophrenia. *Clinical Schizophrenia & Related Psychoses*. 2014; 8(3):129-131.
 77. Buckley PF. Clinical News: New Nature journal, gains in drug development, neurodegeneration versus neurodevelopment and brain changes, neurohistology and risk factors, peer support and recovery, social media and schizophrenia. *Clinical Schizophrenia & Related Psychoses* 2015; 9(4):170-172.
 78. Nuss MA, Robinson B, Buckley PF. Georgia's Innovative Response to GME Expansion. *Journal of the Medical Association of Georgia* 2015; 104(1):10-11.
 79. Buckley PF. Medical College of Georgia at GRU. *Journal of the Medical Association of Georgia* 2015; 104(1):18.
 80. Buckley PF. Clinical News: Putative antipsychotics, Kraepelin and psychosis continuum, obsessive-compulsive disorder and schizophrenia, psychosis trajectory, *Toxoplasmosis gondii* exposure and cognitive impairment, clozapine and polypharmacology. *Clinical Schizophrenia and Related Psychoses* 2015; 9(1):10-12.
 81. Buckley PF. *Shrinks: The Untold Story of Psychiatry*. Book review. *Psychiatric Times* 2015.
 82. Ahmed AO, Buckley PF. Review tempers expectations for peer-led services but further studies are required. *Evid Based Ment Health* 2014; 17(4):123.
 83. Buckley PF. Clinical News: Congress awards, new antipsychotic drug developments and new clinical trials, RAISE, IOM and clinical trials data, precision medicine, double trouble, and early detection. *Clinical Schizophrenia and Related Psychoses* 2015; 9(3):114-116.
 84. Buckley PF. *Schizophrenia Spectrum and Other Psychotic Disorders: DSM-5 Selections*. Book review. *Journal of Psychiatric Practice* 2016; 22(3):257.
 85. Buckley PF. *Schizophrenia and Psychotic Spectrum Disorders*. Book review. Oxford University Press, New York. 2016.
 86. Buckley PF. Clinical News: Antipsychotic drug developments, new clozapine monitoring program, antipsychotic use in dementia, antipsychotic exposure during pregnancy, omega-3, mental illness and premature death, biomarkers, RAISE study, smart phones for schizophrenia. *Clinical Schizophrenia and Related Psychoses* 2016; 9(4):163-165.
 87. Buckley PF. Partnering with Families. *Ask the Expert*. *Focus* 2016; 14 (3): 343-344.
 88. Buckley PF. Market Analysis. *Where we practice: Augusta*. *Journal of the Medical Association of*

- Georgia. 2016; 105(1):14-15.
89. Buckley PF. Clinical News: Antipsychotics updates, prodrome detection, first episode schizophrenia management, legacy through philanthropy. *Clinical Schizophrenia and Related Psychoses* 2016; 10(1):17-20.
 90. Buckley PF. Clinical News: Putative new antipsychotics update and biomarkers for schizophrenia, NIH strategic plan, neuroinflammation beyond schizophrenia, cannabis and neurodegeneration, schizophrenia diagnoses and social media, ACT changes with the times. *Clinical Schizophrenia and Related Psychoses* 2016; 10 (2): 85-86.
 91. Buckley PF, Nasrallah HA. The psychiatry workforce pool is shrinking. What are we doing about it? *Current Psychiatry* 2016; 15(9):23-24, 95.
 92. Buckley PF. Clinical News: Biomarkers, OMICS, “cave fish” and schizophrenia marijuana and psychosis, premature death and schizophrenia, mortality rats and schizophrenia, PRIDE study, weight loss drugs. *Clinical Schizophrenia and Related Psychoses* 2016; 10(3):135-137.
 93. Buckley PF, Miller BJ. Precision medicine for schizophrenia. *NPJ Schizophrenia*. 2017; 3:2.
 94. Buckley PF. Clinical News: Tamminga honored, antipsychotic drug developments, “dirty pot”, neonatal congenital malformation risks with antipsychotics, pharmacogenetics, RAISE program, exercise and schizophrenia. *Clinical Schizophrenia & Related Psychoses* 2017;10(4):187-190.
 95. Buckley PF, Miller B. Rheumatoid arthritis drugs for schizophrenia. *Psychiatric Annals* 2018; 48(5).
 96. Buckley PF. Developing Our Workforce and Advancing Collaborative Care. Reviewing the Clinical Landscape. *Focus* 2017; 15(4):3.
 97. Buckley PF. Clinical News: “dopamine-lite” putative antipsychotics, stem cells, cannabis and relapse, nicotine use disorder, long-acting injectable antipsychotics, low fecundity yet persistence of psychosis, antipsychotic use over course of illness, cognitive remediation, fatty acids and psychosis. *Clinical Schizophrenia and Related Psychoses* 2017; 11(1):26-28.
 98. Buckley PF. Clinical News: update on antipsychotics, selective effects and adjunctive treatments, resilience, plasma levels, biotypes for schizophrenia, recovery, suicide and schizophrenia, texting study, home health. *Clinical Schizophrenia and Related Psychoses* 2017; 11(2):82-84.
 99. Buckley PF, Review of Two x Four Model. A neuroscience-based blueprint for the modern integrated addiction and mental health treatment system. (A. Chambers, author). *Journal of Dual Diagnosis* (in press).
 100. Buckley PF. Clinical News: new antipsychotics, autism and schizophrenia, genetic and other biomarkers, auditory cortex morphology in schizophrenia, phenotyping through drug and nonpharmacologic response, treatment-refractory schizophrenia, smartphones. *Clinical Schizophrenia and Related Psychoses* 2017; 11(3):129-132.
 101. Buckley PF. Clinical News: Putative antipsychotics, depressive equivalents, mortality, immune dysfunction, mobile health. *Clinical Schizophrenia and Related Psychoses* 2018;11(4):193-196.
 102. Buckley PF. Clinical News: new drugs and deliveries, Star Wars biotechnology convergence science, neurobiology of Parkinson’s disease, neurodevelopmental effects of cannabis, cell dormancy, bipolar and schizophrenia commodities, e-cigarettes long-acting injectable antipsychotics. *Clinical Schizophrenia and Related Psychoses* 2018;12(1):5-8.
 103. Buckley PF, Miller BM. Innovative add-on treatments for schizophrenia. *Psychiatric Annals* 2018; 48(5):1-2.

104. Buckley, PF. Clinical News: putative antipsychotics, developmental trajectories, schizophrenia- mood continuum and neurobiological constructs, novel treatments, weight gain. *Clinical Schizophrenia and Related Psychoses*. 2018; 12(2):53-56.
105. Buckley, PF. Reviewing the Clinical Landscape. *Focus*. 2018.
106. Buckley, PF. Clinical News: putative antipsychotics, cannabis and schizophrenia, genetics continuum, treatment refractory, schizophrenia stigma. *Clinical Schizophrenia and Related Psychoses*. 2018; 12(3): 101-104.
107. Buckley PF. Mutability of Psychosis and Medications. *Journal of Psychiatry and Brain Science*. 2018; 3(5):10.
108. Hwang M, Buckley PF. Comorbidity in schizophrenia. *Psychiatric Annals*. 2018; 48(12):544-545.
109. Buckley PF. Clinical News... update on putative antipsychotics... boundaries of psychosis... copy number variants... cerebrospinal fluid analysis... cannabis and schizophrenia... precision medicine and schizophrenia... Suicide and early detection in first episode psychosis. *Clinical Schizophrenia & Related Psychoses*. 2019, 12(4): 145-148.
110. Buckley PF. Neuroinflammation and schizophrenia. *Current Psychiatry Reports*. 2019; 21(8):72.
111. Pandurangi AK, Buckley PF. Neuroinflammation, antipsychotic drugs, and evidence of effectiveness of anti-inflammatory agents in schizophrenia. *Current Topics in Behavioral Neurology*. 2020; 44:227-244.
112. Ripley E, Griffith DG, Yackel T, Buckley PF. Balancing institution and faculty needs. *Group Practice Journal*. 2019; 68(8):24-27.
113. Buckley PF. Resilience and gratitude. *Psychiatric Times*. 2020; XXXVII (11): 14-16
114. Fanous AH, Buckley PF. Update on psychiatric genetics: preparing the way for precision medicine. *Psychiatric Annals*. 2021; 51(4):155-156.
115. Gupta R, Bigdelli TB, Buckley PF, Fanous AH. Genetics of schizophrenia and bipolar disorder: potential clinical applications. *Psychiatric Annals*. 2021; 51(4):158-164.
116. Buckley PF. Generative and generous. *Journal of Dual Diagnosis*. 2021; 17(2):98.

Abstracts

1. Buckley PF, Walshe D, Colohan H, O'Callaghan E, Gibson T, Larkin C, Waddington JL: Violence and schizophrenia. *The Irish Psychologist* 1989; 16: 26.
2. Walshe D, Buckley PF, O'Callaghan E, Colohan H, Gibson T, Larkin C, Waddington JL: Deliberate self-harm and depression in schizophrenia. *The Irish Psychologist* 1989; 16: 25.
3. Colohan H, O'Callaghan E, Buckley PF, Walshe D, Gibson T, Larkin C, Waddington JL: Positive and negative symptoms in schizophrenia. *The Irish Psychologist* 1989; 16: 25.
4. Gibson T, O'Callaghan E, Colohan H, Walshe D, Buckley PF, Larkin C, Waddington JL: The seasonality effect in schizophrenia. *The Irish Psychologist* 1989; 16: 25.
5. Buckley P, Freyne A, Walsh N: Anorexia nervosa in males. *The Irish Psychologist* 1990; 12: 8.
6. Buckley PF, Walshe D, Colohan H, O'Callaghan E, Mulvany F, Larkin C, Waddington JL: Violence and schizophrenia. *Bulletin of the Royal College of Psychiatrists* 1990; 14 (Suppl 1): 42-43.

7. Buckley PF, Freyne A, Walsh N: Anorexia nervosa in males. *Bulletin of the Royal College of Psychiatrists* 1990; 14(Suppl 1): 123.
8. Waddington JL, O'Callaghan E, Buckley PF, Larkin C, Redmond O, Stack J, Ennis JT: Cerebral atrophy, signal hyperintensities and ventricular volume in schizophrenia on MRI: relationship to the presence or absence of tardive dyskinesia. *Schizophrenia Research* 1991; 4(3): 369.
9. Waddington JL, O'Callaghan E, Buckley PF, Larkin C, Redmond O, Stack J, Ennis JT: Early increase in ventricular volume but late cortical atrophy in schizophrenia on MRI. *Biological Psychiatry* 1991; 29, 11S: 317.
10. Buckley PF, O'Callaghan E, Larkin C, Redmond O, Stack J, Ennis JT, Waddington JL: T2 prolongation on magnetic resonance imaging and its relationship to lateral ventricular volume in schizophrenia. *Schizophrenia Research* 1992; 6: 146.
11. Waddington JL, O'Callaghan E, Buckley PF, Larkin C, Redmond O, Stack JP, Ennis JT: Magnetic resonance imaging and spectroscopy in schizophrenia in relation to the neurodevelopmental hypothesis. *Clinical Neuropharmacology* 1992; 15(Suppl. 1): 118A-119A.
12. Buckley PF, Meltzer HY: History of substance abuse and response to clozapine treatment. *Schizophrenia Research* 1993; 9: 258.
13. Buckley PF, Friedman L, Lys C, Findling R, Meltzer HY: Genetic and obstetrical determinants of cerebral morphology on computed tomography in schizophrenia. *Schizophrenia Research* 1993; 9: 195.
14. Buckley PF, Friedman L, Lys C, Elkis H, Meltzer HY: Influences of age and gender on cerebral morphology on computed tomography in schizophrenia. *Schizophrenia Research* 1993; 9: 195.
15. Waddington JL, O'Callaghan E, Buckley PF, Larkin C, Redmond O, Stack JP, Ennis JT, Kinsella A: Minor physical anomalies, other indices of developmental disruption in schizophrenia, and cerebral asymmetry on MRI. *Schizophrenia Research* 1993; 9: 212.
16. Buckley PF, Moore C, Larkin C, Mulvany F, Redmond O, Stack JP, Ennis JT, Waddington JL: ¹H Magnetic resonance spectroscopy of frontal and temporal lobe metabolism in schizophrenia. *Schizophrenia Research* 1993; 9: 194.
17. Buckley PF, Moore C, Long H, Larkin H, Mulvany F, Redmond O, Stack JP, Ennis JT, Waddington JL: Sexual dimorphism, putative neurodevelopmental and cognitive correlates of ¹H-Magnetic Resonance Spectroscopy in Schizophrenia. *Schizophrenia Research* 1994; 11: 169.
18. Waddington JL, Lane A, Buckley PF, O'Callaghan E, Larkin C: Minor physical anomalies as an index of developmental disturbance in schizophrenia to abnormalities of cerebral structure on MRI. *Clinical Neuropharmacology* 1994.
19. Buckley PF, Friedman L, Wu D, Lai S, Meltzer HY, Miller D, Haacke EM, Lewin JS: Functional magnetic resonance imaging of the motor cortex in schizophrenia: procedures and initial observations. *Schizophrenia Research*. 1995; 15: 78.
20. Buckley PF, Cola PA, Hasegawa M, Lys C, Meltzer HY: Plasma levels and dosing strategies in schizophrenic patients receiving clozapine. *Schizophrenia Research*. 1995; 15: 144.
21. Waddington JL, O'Callaghan E, Buckley PF, Madigan C, Redmond O, Stack JP, Kinsella A, Larkin C, Ennis JT: Developmental precursors of tardive dyskinesia in schizophrenia: minor physical anomalies, frontal lobe dysfunction and cerebral structure on MRI. *Schizophrenia Research* 1995; 15: 211.
22. Buckley PF, Donenwirth K, Bayer KE, Lys C, Ibrahim ZY, Schulz SC: Risperidone treatment of schizophrenia in a state hospital. *Schizophrenia Research* 1995; 15: 145.

23. Buckley PF, Bartell JA, Donenwirth K, Lee S, Olivera A, Torigoe FY, Schulz SC: Clozapine and aggression: specificity of treatment response? *Schizophrenia Research* 1995; 15: 144.
24. Simon MR, Buckley PF, Strauss M, Jaskiw GE: Treatment non-responders: a neurobiological investigation. *Schizophrenia Research* 1995; 15: 134.
25. Buckley PF, Krowinski AC, Miller D, Friedman L, Eaton E, Tronetti M: "High-dose" clozapine therapy: clinical and biochemical correlates. *Schizophrenia Research* 1996; 18: 125.
26. Buckley PF, Dean D, Friedman L, Kwon D, Bookstein FL, Lewin JS, Kamath J, Lys C: 3-D surface analysis of the ventricular system in schizophrenia. *Schizophrenia Research* 1996; 18: 186.
27. Buckley PF, Lewin JS, Friedman L, Wu D, Miller DA, Thompson LA, Klein SK, Wise AL, Hedera P, Friedland R, Meltzer HY: Functional magnetic resonance imaging and schizophrenia. *Biological Psychiatry* 1996; 39: 638.
28. Buckley PF, Lys C, Findling R, Schulz SC, Xue M, Ng T: Proton magnetic resonance spectroscopy and aberrant neurodevelopment: frontal lobe metabolism in adolescent-onset schizophrenia and autism. *Schizophrenia Research* 1997; 24: 163.
29. Buckley PF, Cutler N, Silber C, O'Neil J, Mack R: Safety and tolerability of sertindole in elderly patients with dementia. *Schizophrenia Research* 1997; 24: 201.
30. Buckley PF, Miller D, Richman C, Chapman P, Negron A, Friedman L: Electroencephalographic pattern, side effect profile, and clozapine plasma levels in patients receiving 900 mg of clozapine. *Schizophrenia Research* 1997; 24: 264.
31. Buckley PF, Dean D, Friedman L, Kwon D, Bookstein FL, Lewin JS, Kamath J, Lys C: Shape deformity in schizophrenia: a MRI morphometrics study. *Schizophrenia Research* 1997; 24: 140.
32. Buckley PF, Hyde J, Winterich D, Friedman L, Donenwirth K: Sexuality and schizophrenia: behavioral patterns and clinical correlates. *Schizophrenia Research* 1997; 24: 11.
33. Friedman L, Jesberger J, Swales S, Rakow R, Ward K, Pi D, Schulz SC, Buckley PF: A study of head size in adult patients with schizophrenia. *Schizophrenia Research* 1997; 24: 144.
34. Friedman L, Cerny C, Wiechers I, Jellema J, Latimer B, Schulz SC, Buckley PF: Prediction of intracranial volume from post mortem head, stature and body frame measurements: influences of gender, race, and implications for schizophrenia research. *Schizophrenia Research* 1997; 24: 145.
35. Buckley PF, Dean D, Bookstein FL, Friedman L, Kwon D, Lewin JS, Kamath J, Lys C. MRI morphometrics and volumetric analyses of cerebral morphology in schizophrenia. *Schizophrenia Research* 1998; 29: 78.
36. Buckley PF, Friedman L, Dasari M, Schulz SC. Metaanalysis of ³¹P MR spectroscopy studies in schizophrenia. *Schizophrenia Research* 1998; 29: 99.
37. Buckley PF, Robben T, Friedman L, Hyde J, Winterich D. Sexual behavior among inpatients with schizophrenia. *Schizophrenia Research* 1998; 29: 197.
38. Buckley PF. Magnetic resonance spectroscopy and aberrant neurodevelopment. *Biological Psychiatry* 1998; 43: 61S.
39. Buckley PF, Hasan S, Friedman L, Cerny C. Insight, psychopathology and cognitive function in schizophrenia: observations in a state hospital population. *Schizophrenia Research* 1999; 36: 126.
40. Hagger C, Friedman L, Kenny J, Hyde J, Buckley P. Cognitive impairment in substance-abusing patients with schizophrenia. *Schizophrenia Research* 1999; 36: 133.

41. Lys C, Findling R, Friedman L, Schulz SC, Xue M, Ng T, Buckley PF. Frontal lobe metabolism and aberrant neurodevelopment: a comparative MRS study among adolescents with autism, schizophrenia, and healthy subjects. *Schizophrenia Research* 1999; 36: 226.
42. Buckley P, McCarthy M, Chapman P, Richman C, Yamamoto B. Clozapine treatment of comorbid substance abuse in patients with schizophrenia. *Schizophrenia Research* 1999; 36: 272.
43. Dayem MA, Donenwirth K, Popovitz M, Buckley P. Olanzapine efficacy in treatment-refractory schizophrenic patients at a state hospital. *Schizophrenia Research* 1999; 36: 276.
44. Sajatovic M, Donenwirth K, Buckley P. Age-related comparison of health resource utilization in women with serious mental illness. *Schizophrenia Research* 1999; 36: 349.
45. Buckley PF, Lys C, Findling R, Friedman L, Schulz SC, Xue M, Ng T. A MR spectroscopy study of adolescent-onset schizophrenia and autism. *Biological Psychiatry* 1999; 45: 112-113.
46. Buckley P, McCarthy M, Chapman P, Richman C, Yamamoto B. Clozapine treatment of comorbid substance abuse and schizophrenia. *Biological Psychiatry* 1999; 45: 14.
47. Buckley PF. Antipsychotic medications and autism. *Journal of Psychopharmacology* 1999; 13(3): 9.
48. Buckley PF, Friedman L, Jesberger JA, Schulz SC. Do patients with schizophrenia have smaller heads? *Schizophrenia Research* 2000; 41: 125.
49. Buckley PF, McCarthy M, Chapman P, Richman CG, Yamamoto B. Clinical and biochemical correlates of clozapine response in patients with comorbid substance abuse and schizophrenia. *Schizophrenia Research* 2000; 41: 186-187.
50. Buckley PF, Miller DD, Singer B, Donenwirth K. New uses for new antipsychotics. *Schizophrenia Research* 2000; 41:212.
51. Buckley PF, Miller DD, Singer B, Donenwirth K. Expanding use of atypical antipsychotics. *Biological Psychiatry* 2000; 47: 18.
52. Buckley PF, McCarthy M, Chapman P, Richman CG, Yamamoto B. Craving reduction and clozapine response in patients with comorbid substance abuse and schizophrenia. *Biological Psychiatry* 2000; 47: 18-19.
53. Buckley PF, Friedman L, Jesberger JA, Jaskiw GE, Schulz SC. Extracranial size in patients with schizophrenia. *Biological Psychiatry* 2000; 47: 19.
54. Hrouda DR, Resnick PJ, Aronoff M, Caso M, Friedman L, Noffsinger S., Buckley PF. Violence and schizophrenia: initial observations on standards of care. *Schizophrenia Research* 2001; 49: 33.
55. Buckley PF. Comparison of the effects of quetiapine and haloperidol in a cohort of patients with treatment-resistant schizophrenia. *Schizophrenia Research* 2001; 49: 221.
56. Sajatovic M, Sultana D, Bingham CR, Buckley PF. Health resource use in older adults with schizophrenia. *Schizophrenia Research* 2001; 49: 276.
57. Singer B, Buckley PF, Friedman L, Massanyi E, Pamies C. Weight gain, diabetes mellitus, and the pharmacotherapy of schizophrenia. *Schizophrenia Research* 2001; 49: 290.
58. Buckley PF, Hrouda DR, Resnick PJ, Aronoff M, Caso M, Friedman L, Noffsinger S. Violence and schizophrenia: implications for community care. *Schizophrenia Research* 2002; 50.
59. Mahadik SP, Wakade CG, Chiu F-CA, Buckley PF. Atypical antipsychotic induced neurogenesis in adult brain. 2002 NCDEU Abstracts, Boca Raton, FL.

60. Mahadik S, Parikh V, Khan M, Salat P, Kalla A, Buckley P. Risperidone prevents and restores haloperidol-induced oxidative stress-mediated brain injury. *Schizophrenia Research* 2003; 60:112.
61. Friedman L, Hrouda D, Noffsinger S, Resnick P, Buckley PF. Psychometric relationships of insight in patients with schizophrenia who commit violent acts. *Schizophrenia Research* 2003; 60:81.
62. Hrouda D, Resnick P, Friedman L, Noffsinger SJ, Buckley PF. Violence and schizophrenia: further observations on standards of care. *Schizophrenia Research* 2003; 60:40.
63. Parikh V, Khan MM, Brogdon S, Salat P, Buckley PF, Mahadik SP. Effects of risperidone, clozapine and olanzapine versus haloperidol on the expression of nerve growth factor and choline acetyltransferase in rat brain. *Biol Psychiatry* 2003; 53:235.
64. Mahadik SP, Khan MM, Evans D, Buckley PF. Role of leptin and apolipoprotein D in food intake and body mass index in schizophrenia and following its treatment with antipsychotics. *Biol Psychiatry* 2003; 53:445.
65. Mahadik SP, Parikh V, Khan MM, Salat P, Kalla A, Buckley PF. Risperidone prevents and restores haloperidol-induced oxidative stress-mediated brain injury. *Biol Psychiatry* 2003;53:445.
66. Evans D, Khan MM, Parikh V, Coussons C, Brogdon S, Buckley PF, Mahadik SP. Membrane essential polyunsaturated fatty acid metabolism in first episode of psychosis and after treatment with antipsychotics. *Biol Psychiatry* 2003; 53:1805.
67. Mahadik SP, Parikh V, Khan MM, Buckley PF. Differential effects of antipsychotics on nerve growth factor in rat brain. *NCDEU* 2003, p.130.
68. Buckley PF, Dean D, Yerukhimovich M, Han S, Bookstein F, Singer B. Craniofacial dysmorphology in schizophrenia: midline deformation from morphometrics with 3-D facial holography. *Schizophrenia Research* 2003; 60:34.
69. Evans DR, Parikh V, Khan MM, Buckley PF, Mahadik SP. Nerve growth factor in never-medicated first episode psychotic and medicated schizophrenia patients: possible implications for treatment outcome. *Schizophrenia Research* 2003; 60:99.
70. Wilson DR, Petty F, Hammond C, Buckley P. Atypical antipsychotics and hyperglycemia: analysis of 11,994 Ohio DMH subjects. *Schizophrenia Research* 2003; 60:370.
71. Buckley PF, Evans D, Khan MM, Parikh V, Coussons C, Brogdon S, Mahadik SP. Phospholipid abnormalities in first episode psychosis. *Schizophrenia Research* 2004; 61:117.
72. Buckley PF, Hrouda D, Resnick P, Friedman L, Noffsinger SJ. Insight and violence in schizophrenia. *Schizophrenia Research* 2004; 61:10.
73. Buckley PF, Miller DD, Singer B, Arena J. Diabetes and antipsychotic medications. *Neuropsychopharmacology* 2004; 29:5110.
74. Miller DD, Ellingrod VL, Holman TL, Buckley PF. Polymorphism of the genes that code for the 5HT_{2C} receptor, weight gain, and clinical response during clozapine treatment. *Neuropsychopharmacology* 2004; 29:5175.
75. Hrouda D, Resnick P, Buckley P. Guess who is coming to the court clinic: the examination of defendants referred for evaluation. *Schizophrenia Bulletin* 2005; 31(2):225.
76. Miller DD, Ellingrod VL, Holman T, Buckley PF. 5HT_{2C} receptor polymorphisms, weight gain, and clinical response to clozapine response. *Schizophrenia Bulletin* 2005; 31(2):273.
77. Camchong J, Dyckman KA, Buckley PF, McDowell JE. Neural circuitry activity associated with ocular

- motor delayed response task performance in normal and schizophrenia subjects. *Schizophrenia Bulletin* 2005; 31(2):415.
78. Clementz BA, Brown R, Buckley P. Motion detection in relation to MT functioning in schizophrenia. *Schizophrenia Bulletin* 2005; 31(2):451.
 79. Gilmore C, Clementz B, Buckley PF. Interaction of driven oscillatory neural activity and visual evoked potentials in schizophrenia patients. *Schizophrenia Bulletin* 2005; 31(2):459.
 80. Moratti S, Gao A, Clementz BA, Buckley PF. Interaction of driven oscillatory neural activity and visual evoked potentials in schizophrenia patients. *Schizophrenia Bulletin* 2005; 31(2):459.
 81. Buckley PF, Rupnow M, Greenspan A, Gharabawi G, Bossie C, Zhu Y, Koskik-Gonzales C, Ruetsch C, Revicki D, Anand R. Readiness for hospital discharge: relationship with measures of symptom improvement in subjects with schizophrenia. *Schizophrenia Bulletin* 2005; 31(2):477.
 82. Deberdt W, Liu-Seifert H, Csernansky J, Buckley P, Peuskens J, Kollack-Walker S, VanBrunt D. Drug-specific correlates of relapse risk in schizophrenia: A retrospective analysis of randomized, double-blind comparator study of olanzapine versus risperidone. *Schizophrenia Bulletin* 2005; 31(2):490.
 83. Kane JM, Potkin S, Buckley P, Daniel DG. Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. *Schizophrenia Bulletin* 2005; 31(2):490.
 84. Arena J, Singer B, Buckley PF. Physical comorbidity and schizophrenia. *Schizophrenia Bulletin* 2005; 31(2):537.
 85. Stirewalt EM, Miller DD, Singer B, Arena J, Buckley PF. Implementing guideline recommendations for managing metabolic adverse effects of antipsychotic medications. *Schizophrenia Bulletin* 2005; 31(2):570.
 86. Stirewalt EM, Buckley PF, Pillai A, Evans D, Mahadik S. Studies of brain-derived neurotrophic factor in first episode schizophrenia. *Schizophrenia Bulletin* 2007; 33(2): 313-314.
 87. Pillai A, Dhandapani KM, Buckley PF, Mahadik SP. Do neurotrophins have therapeutic potential in schizophrenia?: Erythropoietin prevents haloperidol toxicity through increased expression of BDNF. *Schizophrenia Bulletin* 2007; 33(2): 322.
 88. Kalali AH, Schooler N, Marder S, Vaccarino A, Bilder R, Buckley P, Gharabawi G, Kane J, Lindenmayer JP, Robinson D, Santor D. The ISCDD schizophrenia initiative: A collaborative and data driven initiative for new scale development. *Schizophrenia Bulletin* 2007; 33(2): 435-436.
 89. Talbott S, Buckley P, Eudicone J, McQuade R, Van-Tran Q. Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine – Analyses of the first 12 weeks of three double blind, long term trials. *Schizophrenia Bulletin* 2007; 33(2): 463.
 90. Buckley PF, McEvoy J, Buchanan R, Finnerty M. TMAP and treatment-refractory schizophrenia: so when should I try clozapine? *Schizophrenia Bulletin* 2007; 33(2): 467-468.
 91. Patel JK, Buckley PF, Hamer RM, Woolson S, McEvoy JP, Perkins D, Lieberman JA. Changes in metabolic parameters in first episode schizophrenia following treatment with atypical antipsychotics for 52 weeks: Subset analysis from the café study. *Schizophrenia Bulletin* 2007; 33(2): 504-505.
 92. Buckley PF, Mahadik SP, Khan M, Evans DR. Comparison of leptin levels and obesity between drug-naive first-episode schizophrenia patients and chronically medicated patients. *Schizophrenia Bulletin* 2009; 35 (1): 30.
 93. Fenley GN, Peebles S, Mabe A, Bruce T, Narasimhan M, Frinks L, Williams E, Buckley PF. Recovery and

- schizophrenia: Evaluation of a recovery-based educational program. *Schizophrenia Bulletin* 2009; 35 (1): 133-134.
94. Pillai A, Fulzele S, Buckley PF. Role of c-cbl (an E3 ubiquitin ligase) in BDNF/TRK B signaling in schizophrenia and bipolar disorder. *Schizophrenia Bulletin* 2009; 35 (1): 233-134.
 95. Narasimhan M, Brunette MF, Dawson R, O' Keefe CD, Weeks MH, Buckley PF, Green AI. Long- acting risperidone for schizophrenia and co-occurring alcohol use disorder. *Schizophrenia Bulletin* 2009; 35 (1): 343.
 96. Brunette MF, Green AI, Buckley PF, O' Keefe CD, Dawson R. Quetiapine for the treatment of patients with schizophrenia and co-occurring alcohol use disorder. *Schizophrenia Bulletin* 2009; 35 (1): 371.
 97. Keefe R, Vinogradov S, Medalia D, Buckley P, Cavoff S, D'Souza D, Harvey P, Graham K, Marder S, Miller D, Olson S, Patel J, Velligan D, Walker T, Haim A, Stroup S. Feasibility study of multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN). *Schizophrenia Research*, 2010; 117 (2-3):
 98. Buckley PF, Pillai A, Deficits in Brain Derived Neurotrophic Factor: Potential as an early-phase biomarker for schizophrenia? *Schizophrenia Research*, 2010; 117 (2-3): 125.
 99. Ahmed A, Buckley PF, Mabe A. Taxometric explorations of the latent level association between alcohol/drug use problems and psychosis. *Schizophrenia Bulletin* 2011; 37 (1): 45
 100. Miller B, Buckley PF, Miller A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: Clinical status, symptoms, and antipsychotic effects. *Schizophrenia Bulletin* 2011; 37 (1): 57
 101. Buckley PF, Pillai A, Schooler N, Miller D, Lauriello J, Goff D, Mendeloweiz A, Manskech T, Kopewloweiz A, Wilson D, Kane J. Brain Derived Neurotrophic Factor as a Potential Biomarker for Relapse in Schizophrenia: Initial Observations from The PROACTIVE (Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: Evaluating Efficacy) Study. *Schizophrenia Bulletin* 2011; 37 (1): 83.
 102. Goff D, Freudenreich O, Cather C, Thesen T, Holt D, Sinikova T, Buckley P. Neuroinflammatory biomarkers in schizophrenia: from animal models to clinic. *Schizophrenia Bulletin* 2013; 37(2):S131-S132.
 103. Hamm JP, Oliver WT, Hudgens-Haney ME, Bobilev AM, Buckley PF; McDowell JE, Clementz BA. Stimulus duration and context moderate gamma-band auditory neural abnormalities in schizophrenia. *Schizophrenia Bulletin* 2013; 37(2):S44.
 104. Bodenheimer C, Graham K, Ezeoke A, Buckley PF, Miller B. Urinary tract infections in acute relapse of psychosis. *Schizophrenia Bulletin* 2013; 37(2):S57.
 105. Flatow J, Buckley PF, Miller B. Meta-analysis of oxidative stress in schizophrenia: Clinical status and antipsychotic effects. *Schizophrenia Bulletin* 2013; 37(2):S63.
 106. Hill WD, Miller B, Kondrikova G, Buckley PF. Stem cell signaling in acute relapse of non-affective psychosis. *Schizophrenia Bulletin* 2013; 37(2):S65.
 107. Bobilev AM, Hamm JP, Oliver WT, Hudgens-Haney ME, Buckley PF, Dyckman KA, McDowell JE, Clementz BA. Resting state neural oscillations in schizophrenia and high and low working memory. *Schizophrenia Bulletin* 2013; 37(2):S221.
 108. Hudgens-Haney ME, Bobilev AM, Hamm JP, Oliver WT, Dyckman KA, Buckley PF, McDowell JE, Clementz BA. Deviant modulation of intrinsic neural activity as a function of task difficulty in schizophrenia. *Schizophrenia Bulletin* 2013; 37(2):S231.
 109. Miller B, Mellor A, Buckley PF. Interleukin-6 and cognition in non-affective psychosis. *Schizophrenia*

Bulletin 2013; 37(2):S242-S243.

110. Buckley PF, Schooler NR, Goff D, Hsiao J, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller D, Severe J, Wilson DR, Mintz J, Kane JM. Proactive (preventing relapse oral antipsychotics compared to injectables evaluating efficacy): relapse, symptoms, and medication profiles over 30 months of study. *Schizophrenia Bulletin* 2013; 37(2):S324.
111. Miller BJ, Dias J, Buckley P. An Open-Label Trial of Adjunctive Tocilizumab in Schizophrenia. *Schizophr Res* 2014; 153: S347.
112. Parker DA, Hudgens-Haney M, Oliver W, Hayrynen L, Bobilev A, Knight J, Hart R, Buckley PF, McDowell J, Clementz BA. Reduced steady-state phase synchronization during a cognitive control task. *Schizophrenia Bulletin* 2015; 41(1):S23-S24.
113. Lehrer DS, Pato MT, Miller BJ, Nahhas RW, Malaspina D, Buckley PF, Sobell JL, Pato CN. Risk factors for schizophrenia and the continuum of psychosis: Advanced paternal age (APA) is also associated with psychosis in bipolar disorder. *Schizophrenia Bulletin* 2015; 41(1):S112.
114. Stewart A, Miller B, Schrimsher J, Peeples D, Buckley PF. How connected are people with schizophrenia? Cell phone, computer, email, and social media use. *Schizophrenia Bulletin* 2015; 41(1):S154.
115. Cieslak K, Pato M, Buckley PF, Pato C, Sobell J, Zhao Y, Ahn H, Malaspina D. Traumatic brain injury and psychosis in GPC members. *Schizophrenia Bulletin* 2015; 41(1):S165-166.
116. Hunter KM, Ahmed AO, Mabe PA, Tucker SJ, Buckley PF. Experiential recovery, clinical, and psychosocial functioning in peer specialists with serious mental illness. *Schizophrenia Bulletin* 2015; 41(1):S176.
117. McEvoy J, Millet R, Dretchen K, Morris A, Buckley PF. Medication nonadherence in schizophrenia: Preliminary observations from a novel approach for detecting antipsychotic drug levels. *Schizophrenia Bulletin* 2015; 41(1):S322.
118. Buckley PF, Schooler NR, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz AJ, Miller DD, Wilson DR, Bustillo JR, Kane JM, Looney S. Second and third relapses in a relapse prevention trial of long-acting injectable versus oral antipsychotics: A comparative analysis of successive relapses over 30 months. *Schizophrenia Bulletin* 2015; 41(1):S305.
119. Buckley PF, Bigdeli T, Genovese G, Georgakopoulos P... Pato CN. Risk of Schizophrenia Among Individuals of African and Latino Ancestry: the Genomic Psychiatry Cohort (GPC) Analyses. *Schizophr Bull.* 2020; 46(Suppl 1):S202.